

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 04 July 2001 (04.07.01)	
International application No. PCT/US00/16989	Applicant's or agent's file reference WST91BPCT
International filing date (day/month/year) 21 June 2000 (21.06.00)	Priority date (day/month/year) 23 June 1999 (23.06.99)
Applicant OTVOS, Laszlo, Jr.	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

16 January 2001 (16.01.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer H. Zhou Telephone No.: (41-22) 338.83.38
---	--



P.B.5018 - Patentlaan 2
2280 HV Rijswijk (ZH)
☎ +31 70 340 2040
TX 31651 epo nl
FAX +31 70 340 3016

**Europäisches
Patentamt**

Zweigstelle
in Den Haag
Recherchen-
abteilung


**European
Patent Office**

Branch at
The Hague
Search
division

**Office européen
des brevets**

Département à
La Haye
Division de la
recherche

Hale, Stephen Geoffrey
JY & GW Johnson,
Kingsbourne House,
229-231 High Holborn
London WC1V 7DP
GRANDE BRETAGNE



Datum/Date

08.05.03

Zeichen/Ref./Réf. WST91BEPO	Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n°. 00946829.9-1223-US0016989
Anmelder/Applicant/Demandeur/Patentinhaber/Propriétaire/Titulaire THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

☐ Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.

REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.





European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 00 94 6829

Claim(s) searched incompletely:
1-14

Reason for the limitation of the search:

Present claims 1 to 14 relate to a compound defined by reference to a desirable characteristic or property, namely its resistance to cleavage. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds wherein the dipeptide resistant to cleavage is selected from Ser-Tyr (X and Y) and Asn-Arg (X' and Y').



European Patent
Office

SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 00 94 6829
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	BAJUSZ S & HUDECZ F (ED.): "Peptides 1998, Proceedings of the European Peptide Symposium, 25th, Aug. 30 - Sept. 4, 1998" 1999, AKADEMAI KIADO, BUDAPEST (HUNGARY) XP002239030 * page 786 - page 787 *	1-14	C12N15/12 C12N15/63 C07K14/435 C07K9/00 A61K38/17 G01N33/68
Y	WEINSTEIN B: "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins" 1982, MARCEL DEKKER, INC., NEW YORK AND BASEL XP002032461 * page 267 - page 357 *	1-14	
A	COCIANCICH S ET AL.: "Novel inducible antibacterial peptides from a hemipteran insect, the sap-sucking bug Pyrrhocoris apterus" BIOCHEMICAL JOURNAL, vol. 300, no. 2, 1994, pages 567-575, XP008012290 * the whole document *		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07K C12N A61K G01N
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
INCOMPLETE SEARCH			
The Search Division considers that the present application, or some or all of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims:			
Claims searched completely :			
Claims searched incompletely :			
Claims not searched :			
Reason for the limitation of the search:			
see sheet C			
Place of search		Date of completion of the search	Examiner
THE HAGUE		22 April 2003	Schmidt, Harald
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78956 A1

- (51) International Patent Classification⁷: C12N 15/12, 15/63, 15/82, C07K 7/10, 9/00, A61K 37/02
- (21) International Application Number: PCT/US00/16989
- (22) International Filing Date: 21 June 2000 (21.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/140,606 23 June 1999 (23.06.1999) US
60/154,135 15 September 1999 (15.09.1999) US
- (71) Applicant (for all designated States except US): THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY [US/US]; 3601 Spruce Street, Philadelphia, PA 19104-4268 (US).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): OTVOS, Laszlo, Jr. [US/US]; 801 Mockingbird Lane, Audubon, PA 19403 (US).
- (74) Agents: BAK, Mary, E. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US).
- (81) Designated States (national): AU, CA, JP, US.
- (84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PYRRHOCORICIN-DERIVED PEPTIDES, AND METHODS OF USE THEREOF

(57) Abstract: Modifications of the peptide pyrrhocoricin permit the production of a variety of anti-bacterial or anti-fungal peptides having general formula R¹-Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'-R²[SEQ ID NO:1] or multimeric compositions containing more than a single peptide of that formula. These peptides may be straight chain or cyclic peptides, and may contain one or more non-cleavable bonds. These peptides are characterized by anti-bacterial or anti-fungal activity and metabolic stability in mammalian serum. These peptides are useful in anti-bacterial or anti-fungal pharmaceutical compositions and for further drug development or identification of other antibiotic or anti-fungal compounds.

WO 00/78956 A1

NOVEL PYRRHOCORICIN-DERIVED PEPTIDES,
AND METHODS OF USE THEREOF

This invention was supported in part by National Institute of Health grant Nos.
5 GM45011. The United States government has an interest in this invention.

Field of the Invention

The invention relates generally to novel peptides; more specifically, the invention relates to compositions and methods for killing bacteria or fungus or treating bacterial, fungal or other microbial infections with pyrrhocoricin-based peptides.

10 **Background of the Invention**

In the continuing search for new compounds that can break drug resistance in bacterial infections of humans and other mammalian species, certain anti-bacterial peptides and glycopeptides isolated from insects have been noted as promising candidates for drug development [D. Hultmark, Trends Genet., 9:178-183 (1993); J. P. Gillespie *et al*, Annu. Rev. Entomol., 42:611-643 (1997)]. See, also, International Patent Application No. WO94/05787, published March 17, 1999; French patent No. 2733237, granted Oct. 25, 1996; International Patent Application No. WO99/05270, published February 4, 1999; International Patent Application No. WO97/30082, published August 21, 1997; French patent No. 2695392 granted March 11, 1994 and
20 French patent No. 2732345, granted October 4, 1996.

While many anti-bacterial peptides from other origins kill bacteria by disrupting the cell membrane or cell wall, some of the insect-derived anti-bacterial peptides have an unusual mode of action, i.e., they bind to a currently unknown, stereospecific target molecule [P. Bulet *et al*, Eur. J. Biochem., 238:64-69 (1996)]. Two such peptides are
25 drosocin, a 19 amino acid residue peptide from species of *Drosophila* [P. Bulet *et al*, J. Biol. Chem., 268(20):14893-14897 (1993)] and pyrrhocoricin, a 20 amino acid residue peptide from species of *Pyrrhocoris* [S. Cociancich *et al*, Biochem. J., 300:567-575 (1994)]. Drosocin and pyrrhocoricin are glycopeptides characterized by the presence

of a disaccharide in the mid-chain position. The presence of the sugar increases the *in vitro* anti-bacterial activity of drosocin, but decreases the activity of pyrrhocoricin [P. Bulet *et al*, 1996, cited above; R. Hoffmann *et al*, Biochim. et Biophys. Acta, 1426:459-467 (1999)].

5 Drosocin is moderately active against Gram-positive bacteria. When the native glycosylated drosocin is injected into mice, the glycopeptide shows no anti-bacterial activity, probably due to the peptide's rapid decomposition in mammalian sera [Hoffmann *et al*, 1999, cited above]. While drosocin needs 12-24 hours to kill bacteria *in vitro*, it is completely degraded in diluted human and mouse serum within a four-
10 hour period. Both aminopeptidase and carboxypeptidase cleavage pathways (decomposition at both ends) can be observed.

Native pyrrhocoricin is also a glycosylated peptide. Pyrrhocoricin is more active against Gram-negative bacteria than drosocin, but the peptide is almost completely inactive against Gram-positive strains. Native pyrrhocoricin appears to be
15 more resistant to mouse serum degradation than drosocin, but decomposes quickly in some batches of human serum.

Metabolites from serum stability assays of drosocin and pyrrhocoricin were identified, and the metabolites, lacking as few as five amino terminal or two carboxy terminal amino acids are inactive [Bulet *et al*, 1996 and Hoffmann *et al*, 1999, both
20 cited above). This is further supported by a recent model of the bioactive secondary structure of drosocin, which identifies two reverse turns, one at each terminal region, as binding sites to the target molecule [A. M. McManus *et al*, Biochem., 38(2):705-714 (1999)]. The situation is further complicated by the fact that the degradation speed and pathway of a given peptide in diluted mouse sera are somewhat different
25 from those observed in diluted human sera. Even different batches of human sera degrade the peptides at different rates and may yield different metabolites *in vitro*. The peptide's stability is markedly increased in insect hemolymph where the peptides manifest their biological functions [Hoffmann *et al*, 1999, cited above].

There exists a need in the art for novel anti-bacterial and anti-fungal
30 compounds, novel anti-bacterial and anti-fungal pharmaceutical compositions and

methods of use thereof, and novel compounds which can be employed in drug screening analyses to detect new pharmaceutical antibiotics.

Summary of the Invention

In one aspect, the invention provides a modified peptide which has anti-bacterial or anti-fungal activity, and has the formula [SEQ ID NO: 1]:

R^1 -Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'- R^2 ,

wherein R^1 is a moiety having a net positive charge;

wherein R^2 is selected from the group consisting of a free hydroxyl, an amide, an imide, a sugar and a sequence of one or up to about 15 additional amino acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar. These additional amino acids are independently selected from L-configuration or D-configuration. These additional amino acids may be capable of forming a cyclic peptide by linkage to the N-terminal amino acid. Such an amino acid may be modified by the insertion of a sugar, imide groups and the like. These additional amino acids may also form spacers to cyclize the peptide by bridging between the N- and C- termini of the peptide;

wherein X and Y form a dipeptide, which is Ser-Tyr or is a dipeptide formed of naturally occurring amino acids or unnatural amino acids, the dipeptide being resistant to cleavage by endopeptidases; and wherein X' and Y' form a dipeptide, which is Asn-Arg, or is a dipeptide formed of naturally occurring amino acids or unnatural amino acids, the dipeptide being resistant to cleavage by endopeptidases, each. In one preferred embodiment, this peptide is a cyclic peptide in which R^1 and/or R^2 form an amino acid spacer (which is preferably a sequence duplicating at least a portion of the pyrrocoricin peptide) linking the N- and C-terminal amino acids of the above formula. The peptides of this formula include modified peptides in which one or more conventional amide bonds between amino acids is replaced with a bond resistant to a protease, such as a thio-amide bond or a reduced amide bond. Further a variety of multimeric peptide constructs are included in this invention.

In a further aspect, the invention provides a composition comprising multiple peptides of the formula above in a variety of multimeric constructs. Such compositions containing one or more peptides of this invention may optionally contain a pharmaceutically acceptable carrier.

5 In another aspect, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding the anti-bacterial or anti-fungal peptide or multimeric compositions of the invention in operative association with a regulatory sequence directing the expression thereof in a host cell. In yet a further aspect, the invention provides a host cell transfected or transformed with the above-described
10 nucleic acid molecule.

In another aspect, the invention provides a method of treating a mammalian bacterial or fungal infection comprising administering to a mammal having said infection an effective anti-bacterial or anti-fungal amount of a pharmaceutical composition described herein.

15 In yet another aspect, the invention provides a method for designing anti-bacterial or anti-fungal pharmaceutical compounds. In one embodiment, this method employs a peptide or multimeric construct described herein in a computer modeling program to design a compound which mimics the structure and biological effect of said peptide. In another embodiment, the method employs a peptide or multimeric
20 construct described herein in an assay or computer program for identifying the peptide's receptor on a selected bacterium.

In another aspect the invention provides a screening method for identifying test compounds which compete with the peptides or multimeric compositions of this invention for binding to the unknown receptor on the pathogen. Thereafter, test
25 compounds which compete with the peptides or multimeric constructs of this invention for the receptor are identified and screened for anti-bacterial or anti-fungal use.

In yet a further aspect, the invention provides novel compositions identified or produced by the methods described above.

30 Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

Brief Description of the Drawings

Fig. 1 is a graph illustrating the degradation of de-glycosylated pyrrhocoricin (Peptide #1) and a modified pyrrhocoricin peptide of this invention, i.e., 1-aminocyclohexane carboxylic acid (Chex)-Pyrrhocoricin- β -acetyl-2,3-diamino propionic acid [Dap(Ac)] (Peptide #21) in 25% mammalian sera over time. The different symbols illustrate the pyrrhocoricin or modified peptide in mouse sera (m), in year-old human sera (h1) and in the month-old human sera (h2). The modified peptide is described in detail below in Example 1. The degradation assay is described below in Example 4.

Fig. 2 is a graph indicating the results of an *in vivo* anti-bacterial activity of de-glycosylated pyrrhocoricin (Peptide #1) and (Chex)-Pyrrhocoricin-(Dap (Ac)) (Peptide #21). Three mice per group were used for toxicity (broken lines), and five mice per group were used for efficacy (solid lines). Five additional mice were infected with *E. coli* for negative controls and received 5% dextrose (DS5) instead of test peptides. The results are plotted as Days vs. Survival (which is defined as the time measured from the start of the experiment until the animal is dead or shows clinical signs of infection). The symbols are as follows:

--○-- for 50 mg/kg pyrrhocoricin, toxicity assay control;

--●-- for 50 mg/kg Chex-pyrrhocoricin-Dap(Ac), toxicity assay control;

--|-- for *E. coli* infection, no peptide, as a positive control for infection;

▲ for 10, 25, and 50 mg/kg Chex-pyrrhocoricin-Dap(Ac) as test peptides after infection;

▽ for 50 mg/kg pyrrhocoricin as test peptide after infection; and

△ for 10, 25 mg/kg pyrrhocoricin as a test peptide after infection.

Fig. 3A is a summary of NOE connectivities for de-glycosylated pyrrhocoricin. The intensities are indicated by the thickness of the line.

Fig. 3B is a summary of NOE connectivities for the native pyrrhocoricin containing a Gal-GalNAc disaccharide moiety of Thr 11 (Peptide #2). The intensities are indicated by the thickness of the line.

Fig. 3C is a graph showing the deviations from the α H chemical shifts from their 'random coil' values for de-glycosylated pyrrhocoricin (Peptide #1), indicated as

a black bar, and for its native counterpart, containing a Gal-GalNAc disaccharide moiety of Thr 11 (Peptide #2), indicated by a striped bar. The random coil values are corrected for sequence specific shift of 0.29 ppm for residues preceding Pro.

Detailed Description of the Invention

5 The present invention provides modified peptides and multimeric compositions of such peptides having anti-bacterial or anti-fungal activity. The peptides are structurally based on the naturally occurring glycosylated peptide, pyrrhocoricin. The peptides and/or multimeric peptide constructs of this invention, which are modified to delete the mid-peptide glycosylation, are characterized by the high anti-bacterial or
10 anti-fungal potency *in vitro* of the unmodified pyrrhocoricin peptide, and provide good metabolic stability in mammalian serum.

A. *Peptides of the Invention*

 According to this invention, preferred anti-bacterial or anti-fungal peptides based on pyrrhocoricin are defined by the following formula

15 R^1 -Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'- R^2 [SEQ ID NO: 1]. As used in the above formula, the N-terminal R^1 is any moiety which can provide a net positive charge on the N-terminus of the modified peptide.

 Thus, for example, R^1 may be selected from one or more of the following groups:

- 20 (a) a straight chain, branched, cyclic or heterocyclic alkyl group,
 (b) a straight chain, branched, cyclic or heterocyclic alkanoyl group,
 (c) a positively charged reporter group; and/or
 (d) one or up to 15 additional amino acids independently selected from
L-configuration or D-configuration amino acids, optionally substituted with a straight
25 chain, branched, cyclic or heterocyclic alkyl group, a straight chain, branched, cyclic or heterocyclic alkanoyl group, or a reporter group. The amino acids may be naturally occurring amino acids or unnatural amino acids, such as D configuration amino acids, or amino acids which are capable of cyclizing the peptide by attachment to a carboxy terminal amino acid. The amino acid may be further modified by the insertion of

modifying sugars, imide groups and the like. These amino acids may also form spacers, as described below, to cyclize the peptide by bridging between the N- and C-termini of the peptide. A variety of methods for producing non-natural amino acids are known and may be selected by one of skill in the art.

5 In one example of the (a) group above, the positively charged 1-aminocyclo-hexane carboxylic acid (Chex) is employed as R¹. In an embodiment of (d), the R¹ group is formed by one or more positively charged amino acid residues or amino acid sequences. For example, R¹ may be a single positively charged amino acid such as L-Val- or D-Val-. R¹ may be a sequence of amino acids with a net positive charge, such as Arg-Val-, Lys-Val-, Lys-Val-Asp-Lys-Val- [SEQ ID NO: 5], and
10 -Arg-Pro-Pro-Thr-Pro-Arg-Pro-Leu-Lys-Val- [SEQ ID NO: 3]. In still other embodiments, such additional amino acids are modified by an acetyl group, providing that a net positive charge results. Some examples of these R¹ groups are Acetyl-Arg-Val-; Acetyl-Lys-Val-; and Acetyl-Lys-Val-Asp-Lys-Val- [SEQ ID NO: 29].
15 Acetylation alone with Val has been found to extinguish the positive charge.

In still other embodiments of peptides falling within this formula, the R¹ group is a positively charged moiety which can function as a reporter group (c) for detection purposes. A reporter group may be defined as a moiety which is capable, alone or in concert with other compositions or compounds, of providing a detectable
20 signal. The reporter may be interactive to produce a detectable signal. Most desirably, the reporter is detectable visually, e.g. colorimetrically. A variety of enzyme systems have been described in the art which will operate to reveal a colorimetric signal in an assay. As one example, glucose oxidase (which uses glucose as a substrate) releases peroxide as a product. Peroxidase, which reacts with peroxide and a hydrogen donor
25 such as tetramethyl benzidine (TMB) produces an oxidized TMB that is seen as a blue color. Other reporters include horseradish peroxidase (HRP) or alkaline phosphatase (AP), and hexokinase in conjunction with glucose-6-phosphate dehydrogenase which reacts with ATP, glucose, and NAD⁺ to yield, among other products, NADH that is detected as increased absorbance at 340 nm wavelength.

Other reporter molecules that may be utilized in the methods of this invention are biotin-avidin, fluorescent compounds such as fluorescein, green and blue fluorescent proteins; and radioactive compounds or elements, such as radioactive iodine, and the like. For example, in some peptides of this invention the R¹ group is the reporter biotin bound to a lysine-valine dipeptide by a covalent bond. Still another peptide of this invention contains a R¹ (d) group which is a reporter group covalently bonded to one or more amino acid residues, resulting in a net positive charge, for example, a 5(6) carboxyfluorescein functionalized-Lys-Val-. Such reporters for attachment to the N-termini of the peptides of this invention may be readily selected from among numerous compositions known and readily available to one skilled in the art of diagnostic assays. The above-listed reporters are understood to be non-exclusive.

Still other peptides of this invention are cyclic peptides, and in these peptides, R¹ is an amino acid "spacer". Spacers are sequences of greater than 3 amino acids which are interposed between the normal N-terminus and C-terminus of the modified pyrrhocoricin. These spacers permit linkage therebetween without imposing any adverse restraint upon the molecular structure. Spacers may also contain restriction endonuclease cleavage sites to enable separation of the sequences, where desired. Desirably, spacers duplicate a portion of the pyrrhocoricin peptide. Suitable spacers or linkers are known and may be readily designed and selected by one of skill in the art. In one embodiment, an amino acid spacer is greater than 5 amino acid residues in length. In a preferred embodiment, the amino acid spacer is greater than 10 amino acid residues in length. The amino acid residues in the spacer may be a sequence of any natural or unnatural amino acids. In an exemplary spacer, the inventor incorporated a sequence which duplicated part of the native pyrrhocoricin, e.g. -Arg-Pro-Pro-Thr-Pro-Arg-Pro-Leu-Lys-Val- [SEQ ID NO: 3]. The Val in this R¹ group is linked to the N-terminal Asp of the formula and the N-terminal amino acid of R¹ is linked by a covalent bond to the C-terminal amino acid of R².

The R² group of peptides of the above formula may be a free hydroxyl, an amide, an imide, a sugar, or a sequence of one or up to about 15 additional amino

acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar. The amino acids may be naturally occurring amino acids or unnatural amino acids, such as D configuration amino acids. The additional amino acids may be capable of forming a cyclic peptide by attaching to an amino terminal amino acid. These amino acids may also be modified by insertion of a sugar, imide groups and the like. These additional amino acids may also form spacers, as described above for R¹, to cyclize the peptide by bridging between the N- and C- termini of the peptide. A variety of methods for producing non-natural amino acids are known and may be selected by one of skill in the art. For example, in some peptides, R² is D-Asn, L-Asn, Asp, or Asn-R³, wherein R³ is a sugar. In some embodiments R³ is 2-acetamido-2-deoxyglucose; in other preferred embodiments, the R³ is triacetyl 2-acetamido-2-deoxyglucose. In other embodiments of the peptides of this invention R² is a β -acetyl-2,3-diamino propionic acid group (DAP(Ac)).

In this formula, X-Y represent two adjacent amino acids which are either Ser-Tyr, or are adjacent amino acids which are resistant to cleavage by endopeptidases. In this formula, X'-Y' represent two adjacent amino acids which are Asn-Arg, or are adjacent amino acids which are resistant to cleavage by endopeptidases. Still other peptides according to the above formula are characterized by having at least one, and preferably more, amino acids altered to the corresponding D amino acid.

The peptides of this formula include modified peptides in which the amino acids may be connected by conventional amide bonds. Alternatively, modified peptides include those in which one or more of the natural or unnatural amino acids may be connected by bonds resistant to proteases, such as, a thioamide bond or a reduced amide bond. Such modifications of the bonds between amino acids may change the conformation of the peptide. Other backbone-modifications of these peptides are also anticipated to improve proteolytic stability and yield analogs with slightly modified activity spectrum. Such modifications include those described for another anti-bacterial peptide in J. E. Oh *et al*, J. Peptide Res., 54:129-136 (1999).

Preferably, one or more of said peptides is a synthetic peptide fused to a second moiety, which moiety enhances the bioavailability of said peptide.

B. *Multimeric Compositions of the Invention*

In another embodiment, multiple peptides of the formula described
5 above may be organized in multimeric constructs or compositions. For example, optional amino acids (e.g., -Gly-Ser-) or other amino acid or chemical compound spacers may be included at the N - or C - termini of the peptides for the purpose of linking two or more peptides together or to a carrier. This composition may take the form of one or more of the above-described peptides expressed as a synthetic peptide
10 coupled to a carrier protein. Alternatively, a composition may contain multiple peptides, each expressed as a multiple antigenic peptide, optionally coupled to a carrier protein. Alternatively, the selected peptides may be linked sequentially and expressed as a recombinantly produced protein or polypeptide. As one embodiment, multiple peptides are linked sequentially, with and without spacer amino acids therebetween, to
15 form a larger recombinant protein. Alternatively, the recombinant protein may be fused in frame with a carrier protein.


In one embodiment of a multimeric construct containing at least two of the above-defined peptides (which may be the same or different peptides of the formula), one peptide is attached to any amino acid of the other peptide(s). Any
20 number of additional peptides may be attached to any amino acid of the other peptides in the composition. In another embodiment of a multimeric composition containing at least two peptides, the second or additional peptides are attached to a branched construct of the other peptides in the composition. Alternatively, each additional peptide is covalently linked to R² of another peptide in the composition.

25 In another embodiment of a multimeric construct or composition containing at least two of the peptides, at least one or more of the peptides is attached to a carrier. In another embodiment, one or more of said peptides is a synthetic peptide fused to a carrier protein. Still alternatively multiple of the above-described peptides with or without flanking sequences, may be combined sequentially in a
30 polypeptide. The peptides or this polypeptide may be coupled to the same carrier, or

different peptides may be coupled individually as peptides to the same or a different immunologically inert carrier proteins.


Suitable carrier proteins may enhance stability or delivery, improve the production, or change the activity spectrum of the peptide. As a few well-known examples, such carrier moieties may be human albumin, polyethylene glycol, other biopolymers or other naturally or non-naturally occurring polymers. In one embodiment, the moiety is desirably a protein or other molecule which can enhance the stability of the peptide. One of skill in the art can readily select an appropriate conjugation moiety.

One desirable example of a multimeric composition according to this invention has the structure of a multi-(peptide [SEQ ID NO: 4]) construct as follows:



In yet another embodiment, the peptides may be in the form of a multiple antigenic peptide ("MAP"). Such a construct may be designed employing the MAP system described by Tam, Proc. Natl. Acad. Sci. USA, 85:5409-5413 (1988).

This system makes use of a core matrix of lysine residues onto which multiple copies of the same peptide of the invention are synthesized as described [see, e.g., D. Posnett *et al.*, J. Biol. Chem., 263(4):1719-1725 (1988)]. Each MAP contains multiple copies of one or more of the peptides or this invention. One embodiment of a MAP contains at least three, and preferably four or more peptides. One preferred embodiment contains a β -alanine substituent on the poly-lysine core. One particularly desirable multiple antigenic complex has the formula



In one preferred embodiment of this structure, each peptide is the same and is
[SEQ ID NO: 10]:



One of skill in the art may readily make any number of multimeric constructs from the peptides of the formula identified above with resort to only conventional skills and knowledge in light of this specification. All such multimeric compositions and constructs are intended to be included in this invention.

C. *Methods of Production*

Such peptides and multimeric compositions may be produced synthetically or recombinantly by conventional methods. Specific embodiments of pyrrococorcin-derived anti-bacterial/anti-fungal peptides of this invention are disclosed in detail in Example 1 below. Preferably, the peptides of the invention are prepared conventionally by known chemical synthesis techniques. Among such preferred techniques known to one of skill in the art are included the synthetic methods described by Merrifield, *J. Amer. Chem. Soc.*, 85:2149-2154 (1963) or as detailed in Example 1.

Alternatively, the peptides or multimeric compositions of this invention may be prepared by known recombinant DNA techniques by cloning and expressing within a host microorganism or cell a DNA fragment carrying a nucleic acid sequence encoding one of the above-described peptides. Coding sequences for these peptides can be prepared synthetically [W. P. C. Stemmer et al, *Gene*, 164:49 (1995)]. Coding sequences can be derived from bacterial RNA by known techniques, or from available cDNA-containing plasmids. Conventional molecular biology techniques, and site-directed mutagenesis may be employed to provide desired peptide sequences. Nucleic acid sequences encoding these peptides may be used in cloning and expressing the peptide compositions of this invention in various host cells well known in recombinant technology, e.g., various strains of *E. coli*, *Bacillus*, *Streptomyces*, and *Saccharomyces*, mammalian cells, (such as Chinese Hamster ovary cells (CHO) or

COS-1 cells), yeast and insect cells or viral expression systems, such as baculovirus systems. The selection of other suitable host cells and methods for transformation, culture, amplification, screening and product production and purification can be performed by one of skill in the art by reference to known techniques. See, e.g.,
5 Gething and Sambrook, Nature, 293:620-625 (1981). When produced by conventional recombinant means, the peptides of this invention may be isolated either from the host cell by conventional lysis techniques or from cell medium by conventional methods, such as chromatography. See, e.g., Sambrook et al, Molecular Cloning. A Laboratory Manual., 2d ed., Cold Spring Harbor Laboratory, New York
10 (1989).

The resulting peptide or multimeric construct is screened for antibiotic or antifungal efficacy and/or metabolic stability by *in vitro* and *in vivo* assays, such as those described in the examples and in the art. These peptides generally have
15 "significant" metabolic stability in mammalian serum, i.e., the peptides are stable for at least 2 hours in serum. More preferred peptides are stable for at least 4 hours in serum. Still more preferred peptides of this invention are stable in serum for greater than 8 hours.

D. Pharmaceutical Compositions of the Invention and Methods of Treatment

20 The compositions of this invention are designed to treat infection by the selected bacterium or fungus of an infected mammal, e.g., human. At least one, or alternatively, several of the peptides or multimeric constructs of the present invention may be formulated into an anti-bacterial or anti-fungal composition with a pharmaceutically acceptable carrier and other optional components. For use in such
25 compositions, the selected peptide may be produced preferably synthetically, but also recombinantly, as disclosed above.

The peptides may be employed in pharmaceutical compositions individually. Alternatively, for the purposes of enhancing pharmacokinetics or bioavailability without eliciting immune responses, one or more peptides may be fused

or conjugated to other moieties as described above. Any number of single peptides or multimeric constructs may be mixed together to form a single composition.

As pharmaceutical compositions, these compositions are admixed with a pharmaceutically acceptable vehicle or carrier suitable for administration as a protein composition. These peptides may be combined in a single pharmaceutical preparation for administration. Suitable pharmaceutically acceptable carriers for use in a pharmaceutical proteinaceous composition of the invention are well known to those of skill in the art. Such carriers include, for example, saline, buffered saline, liposomes, oil in water emulsions and others. The compositions may further include a detergent to make the peptide more bioavailable, e.g., octylglucoside. The present invention is not limited by the selection of the carrier or detergent.

Alternatively, the pharmaceutical compositions may be delivered as nucleotide sequences or may contain sequences which express the peptide or proteins of the invention in the host cell, which peptides are then secreted from the host cells. Suitable vehicles for direct DNA, plasmid nucleic acid, or recombinant vector administration include, without limitation, saline, sucrose, protamine, polybrene, polylysine, polycations, proteins, or spermidine, etc. [See e.g., International Patent Application No. WO94/01139].

Pharmaceutical compositions of this invention may contain other active agents, such as conventional antibiotics, such as vancomycin [see, e.g., International Patent Application No. WO98/40401, published March 10, 1998, incorporated by reference herein]. Alternatively, pharmaceutical compositions may be administered with other anti-pathogenic molecules or antibiotic compounds, such as conventional anti-fungals, e.g., itraconazole.

The pharmaceutical compositions may also be formulated to suit a selected route of administration, and may contain ingredients specific to the route of administration [see, e.g., Remington: The Science and Practice of Pharmacy, Vol. 2, 19th edition (1995)]. The preparation of these pharmaceutically acceptable compositions, from the above-described components, having appropriate pH isotonicity, stability and other conventional characteristics is within the skill of the art.

A method of treating a mammalian bacterial or fungal infection involves administering to an infected mammal an effective anti-bacterial or anti-fungal amount of a pharmaceutical composition described above. The method is useful in the treatment of infection caused by a Gram negative bacterium or Gram positive bacterium, such as those specifically identified in Example 2. The method may also be useful to treat fungal infections of the skin, nails, mucus membranes and intestines, e.g., candidiasis.

According to this invention, a pharmaceutical composition as described above may be administered by any appropriate route, but preferably by a route which transmits the peptide directly into the blood, e.g., intravenous injection. Other routes of administration include, without limitation, oral, intradermal, transdermal, intraperitoneal, intramuscular, intrathecal, subcutaneous, mucosal (e.g., intranasal), and by inhalation. If administered in the form of a nucleic acid preparation, e.g., wherein the sequence of the peptide is expressed in a recombinant viral vector or as naked DNA in a plasmid, the route is preferably intramuscular.

The amount of the protein, peptide or nucleic acid sequences of the invention present in each anti-bacterial effective dose is selected with regard to consideration of the pathogen causing the infection, the severity of infection, the patient's age, weight, sex, general physical condition and the like. The amount of active component required to induce an effective anti-bacterial or anti-fungal effect without significant adverse side effects varies depending upon the pharmaceutical composition employed and the optional presence of other components, e.g., antibiotics, anti-fungals and the like. Generally, for the compositions containing protein/peptide, or fusion protein, each dose will comprise between about 50 μ g peptide/kg patient body weight to about 10 mg/kg. A more preferred dosage may be about 500 μ g/kg of peptide. A more preferred dosage may be greater than 1 mg/kg or greater than 5 mg/kg. Other dosage ranges may also be contemplated by one of skill in the art. For example, dosages of the peptides of this invention may be similar to the dosages discussed for other peptide antibiotics, such as drosocin, although the peptides of this invention appear to be more potent than drosocin. See e.g., International Patent

Application Nos. WO94/05787, WO99/05270, WO97/30082; and French patent Nos. 2733237, 2695392 and 2732345, among others. It has been noted for de-glycosylated pyrrhocorin, that a dosage of about 50 mgs/kg body weight, enhances the infection. It has been surprisingly discovered that an anti-bacterial and/or anti-fungal effect results from administration of a dosage of deglycosylated pyrrhocorin of less than 25 mgs/kg body weight, or preferably less than 10 mg/kg body weight.

Initial doses of the modified pyrrhocorin of this invention may be optionally followed by repeated administration for a duration selected by the attending physician. Dosage frequency may also depend upon the factors identified above, and may range from 1 to 6 doses per day for a duration of about 3 days to a maximum of no more than about 1 week.

E. Use of the Peptides of this Invention in Drug Design, Screening and Development

The peptides and polynucleotide sequences of the present invention may also be used in the screening and development of chemical compounds, small molecules or proteins which mimic the structure or activity of the peptides of this invention, and thus have utility as therapeutic drugs for the treatment of bacterial or fungal infections. These peptides may also be employed in assays to identify and isolate the stereospecific receptor located on the microorganisms against which the peptides are effective and with which they interact to achieve their anti-bacterial or anti-fungal effect. Identification of this receptor may also permit use of a variety of known techniques to design and develop other drugs having the anti-bacterial or anti-fungal effect of the peptides of this invention.

In one such embodiment, the peptides are employed in a suitable competitive assay method with test compounds to assess the ability of the test compound to competitively displace the peptide from binding to its presently unknown receptor on the pathogen. The steps of such a competitive assay may be readily determined by one of skill in the art. Where desired, and depending on the assay selected, a microorganism (e.g., bacterium or fungus) to which the selected peptide(s) are known to bind, e.g., *E. coli* strains, may be immobilized directly or indirectly on a

suitable surface, e.g., in an ELISA format. Such immobilization surfaces are well known. For example, a wettable inert bead may be used. Further, the ligand may be bound to a 96 well plate. Thereafter selected amounts of the test compounds and the peptides of this invention are exposed to the immobilized microorganism and those test compounds selected which can compete with the peptides for binding to the immobilized microorganism. Once those test compounds which compete with the peptides for binding to the receptor on the bacteria or fungi are identified, they may be further screened for anti-bacterial or anti-fungal activities in the methods described in the examples below. It is within the skill of the art to prepare other conventional assay formats for identification of test compounds which compete with the peptides of this invention for binding to the unknown receptor.

Still another assay enables isolation of the receptor and thus the testing and identification of new peptides when the receptor is known. A selected peptide, such as the Biotin-K-pyrrhocoricin (Peptide 18) may be mixed with a French-pressed lysate of *E. coli* and the mixture incubated overnight. The mixture is centrifuged and the supernatant is loaded onto an agarose column to which an anti-biotin monoclonal antibody is conjugated. The column-bound receptor (and the attached biotin-K-pyrrhocoricin peptide) is eluted with a glycine buffer (pH 2.1). The full-sized receptor or its tryptic fragments are submitted to peptide sequencing and mass spectrometry. Alternatively the anti-biotin monoclonal antibody can be replaced with avidin or streptavidin. Yet another way is to couple other reporter groups to the pyrrhocoricin or Lys-pyrrhocoricin peptides, and isolate the receptor by using a monoclonal antibody or other specific binding partner to the reporter group.

Once the receptor is identified, it can be used to identify peptides other than pyrrhocoricin or its analogs that bind to that receptor. The following method may be used to verify the identity of the receptor. Preferably the peptides carry a fluorescing or fluoresceinating reporter group, such as fluorescein-Lys-pyrrhocoricin (Peptide 19). A 2 nM solution of fluorescein-labeled test peptide is mixed with a PBS solution of the receptor in which the concentration of the receptor varies from 1 nM to 100 μ M. The binding curve is measured by fluorescence polarimetry.

The identity of the receptor is not essential to the performance of such assays. Identification of useful anti-bacterial/anti-fungal test compounds permit the screening and development of identification, e.g., the screening of combinatorial libraries, of non-peptide antibiotics which mimic the activity of a peptide of this invention.

Other assays and techniques also exist for the identification and development of compounds and drugs which mimic the structure or activity of a peptide of this invention. These include the use of phage display system for expressing the peptide(s), and the use of a culture of transfected *E. coli* or other microorganism to produce the peptides for binding studies of potential binding compounds. See, for example, the techniques described in G. Cesarini, FEBS Letters, 307(1):66-70 (July 1992); H. Gram *et al*, J. Immunol. Meth., 161:169-176 (1993); C. Summer *et al*, Proc. Natl. Acad. Sci., USA, 89:3756-3760 (May 1992), incorporated by reference herein.

Other conventional drug screening techniques may be employed using the peptides and polynucleotide sequences of this invention. As one example, a method for identifying compounds which specifically bind to a peptide of this invention can include simply the steps of contacting a selected peptide with a test compound to permit binding of the test compound to the peptide; and determining the amount of test compound, if any, which is bound to the peptide. Such a method may involve the incubation of the test compound and the anti-bacterial/anti-fungal peptide immobilized on a solid support.

Typically, the surface containing the immobilized ligand is permitted to come into contact with a solution containing the peptide and binding is measured using an appropriate detection system. Suitable detection systems include the streptavidin horse radish peroxidase conjugate, direct conjugation by a tag, e.g., fluorescein. Other systems are well known to those of skill in the art. This invention is not limited by the detection system used.

Another method of identifying compounds which specifically bind to the peptides of this invention can include the steps of contacting the peptide, immobilized on a solid support with both a test compound and a proposed receptor for the peptide

to permit binding of the receptor to the peptide; and determining the amount of the receptor which is bound to the peptide.

The peptides of the present invention are also useful in assays to identify the stereospecific receptor with which these peptides interact to produce their anti-bacterial effect. Such assays and the identification of the receptor enable additional screening of further pathogens against which the peptides or test compounds as identified above are effective peptides and/or pharmaceutical compounds that bind the same receptor and have an antibiotic effect.

A compound which has structural similarity to the peptide, or the binding portion of the peptide to the receptor may also be computationally evaluated and designed by means of a series of steps in which chemical entities or fragments are screened and selected for their ability to associate with the peptides of this invention. One skilled in the art may use one of several methods to screen chemical entities or fragments for their ability to mimic the structure of these peptides and more particularly to identify the peptide structure that binds with the stereospecific receptor of pyrrococin. This process may begin by visual inspection of, for example, a three dimensional structure of the peptides of this invention on the computer screen. Selected fragments or chemical entities may then be positioned in a variety of orientations to determining structural similarities, or docked, within a putative binding site of the peptide.

Specialized computer programs that may also assist in the process of selecting fragments or chemical entities similar to the peptides, or entities which can interact with the peptides and thus mimic the receptor, include the GRID program available from Oxford University, Oxford, UK. [P. J. Goodford, "*A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules*", *J. Med. Chem.*, **28**:849-857 (1985)]; the MCSS program available from Molecular Simulations, Burlington, MA [A. Miranker and M. Karplus, "*Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method*", *Proteins: Structure, Function and Genetics*, **11**:29-34 (1991)]; the AUTODOCK program available from Scripps Research Institute, La Jolla, CA [D. S.

Goodsell and A. J. Olsen, "*Automated Docking of Substrates to Proteins by Simulated Annealing*", Proteins: Structure, Function, and Genetics, **8**:195-202 (1990)]; and the DOCK program available from University of California, San Francisco, CA [I. D. Kuntz et al, "*A Geometric Approach to Macromolecule-Ligand Interactions*", J. Mol. Biol., **161**:269-288 (1982)], and software such as Quanta and Sybyl, followed by energy minimization and molecular dynamics with standard molecular mechanics force fields, such as CHARMM and AMBER. Additional commercially available computer databases for small molecular compounds include Cambridge Structural Database, Fine Chemical Database, and CONCORD database [for a review see Rusinko, A., Chem. Des. Auto. News, **8**:44-47 (1993)].

Once suitable chemical entities or fragments have been selected, they can be assembled into a single compound or inhibitor. Assembly may proceed by visual inspection of the relationship of the fragments to each other on the three-dimensional image displayed on a computer screen in relation to the structure of the peptide. Useful programs to aid one of skill in the art in connecting the individual chemical entities or fragments include the CAVEAT program [P. A. Bartlett et al, "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules", in Molecular Recognition in Chemical and Biological Problems, Special Pub., Royal Chem. Soc. **78**, pp. 182-196 (1989)], which is available from the University of California, Berkeley, CA; 3D Database systems such as MACCS-3D database (MDL Information Systems, San Leandro, CA) [see, e.g., Y. C. Martin, "3D Database Searching in Drug Design", J. Med. Chem., **35**:2145-2154 (1992)]; and the HOOK program, available from Molecular Simulations, Burlington, MA.

Compounds that mimic a peptide of this invention may be designed as a whole or "*de novo*" using methods such as the LUDI program [H.-J. Bohm, "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors", J. Comp. Aid. Molec. Design, **6**:61-78 (1992)], available from Biosym Technologies, San Diego, CA; the LEGEND program [Y. Nishibata and A. Itai, Tetrahedron, **47**:8985 (1991)], available from Molecular Simulations, Burlington, MA; and the LeapFrog program, available from Tripos Associates, St. Louis, MO. Other

molecular modeling techniques may also be employed in accordance with this invention. See, e.g., N. C. Cohen et al, "Molecular Modeling Software and Methods for Medicinal Chemistry", J. Med. Chem., 33:883-894 (1990). See also, M. A. Navia and M. A. Murcko, "The Use of Structural Information in Drug Design", Current Opinions in Structural Biology, 2:202-210 (1992). For example, where the structures of test compounds are known, a model of the test compound may be superimposed over the model of the peptide of the invention. Numerous methods and techniques are known in the art for performing this step, any of which may be used. See, e.g., P.S. Farmer, Drug Design, Ariens, E.J., ed., Vol. 10, pp 119-143 (Academic Press, New York, 1980); U.S. Patent No. 5,331,573; U.S. Patent No. 5,500,807; C. Verlinde, Structure, 2:577-587 (1994); and I. D. Kuntz, Science, 257:1078-1082 (1992). The model building techniques and computer evaluation systems described herein are not a limitation on the present invention.

Thus, using these computer evaluation systems, a large number of compounds may be quickly and easily examined and expensive and lengthy biochemical testing avoided. Moreover, the need for actual synthesis of many compounds is effectively eliminated.

Once identified by the modeling techniques, the proposed "new anti-bacterial or anti-fungal" compound may be tested for bioactivity using standard techniques, such as the *in vitro* assay of Example 2 below. Suitable assays for use herein include, but are not limited to, the assays shown below in the examples to detect the anti-bacterial effect of the peptides of this invention. However, other assay formats may be used and the assay formats are not a limitation on the present invention.

The following examples illustrate various aspects of this invention. These examples do not limit the scope of this invention which is defined by the appended claims.

EXAMPLE 1: PRODUCTION OF PEPTIDES OF THIS INVENTION

Modified pyrrolic peptides were designed by conventional peptide synthesis techniques. Peptides were assembled on solid-phase using a Milligen 9050

continuous flow automated peptide synthesizer on a Fmoc-PAL-polyethylene glycol-polystyrene copolymer resin with an initial load of 0.17 mmole/g (PerSeptive Biosystems, Warrington, UK) using standard Fmoc chemistry [G. B. Fields *et al*, Int. J. Pept. Protein Res., **35**:161-124 (1990)]. A 4-molar excess of the acylating amino acids and 1-hydroxy-7-azabenzotriazole uronium salt (HATU) activation were used, as recommended for the synthesis of complex peptides [Y. Angell *et al*, Tetrahedron Lett., **35**:5891:5894 (1994)]. The side chain protecting groups were trityl for Asn, *tert*-butyl ether for Tyr, Ser and Thr, *tert*-butyl ester for Asp, 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl for Arg, and *tert*-butoxy-carbonyl for Lys. A glycosylated Asn residue was incorporated in the same manner as unmodified amino acids. Fmoc diaminopropionic acid (Bachem Biosciences) was acetylated with equimolar amounts of pentafluorophenyl acetate prior to peptide synthesis and was used for peptide assembly without any further purification. The glycopeptides were synthesized from commercially available glycoaminoacid building blocks, including Fmoc-Thr [Gal(Ac₄)-GalNAc(Ac₂)]-OH and Fmoc-Asn[GlcNAc(Ac₃)]-OH (Novabiochem, San Diego, Ca). Peptides were cleaved from the solid support by TFA in the presence of *m*-cresol (5%), ethane-dithiol (2.5%), thioanisole (5%), and water (5%) as scavengers for 2-3 hours. Deacetylation of the sugar hydroxyl groups was accomplished by a 2 minute treatment with 0.1 M NaOH. After cleavage, peptides were purified by reversed phase high performance liquid chromatography (RP-HPLC). The final products were characterized by amino acid analysis and matrix assisted laser desorption/ionization (MALDI-MS) by standard methods. Mass spectra verified the anticipated composition of the peptides.

The modifications of the unmodified pyrrhocoricin according to this invention include – terminal and C- terminal modifications to protect the peptide from exopeptidase cleavage. Two endopeptidase cleavage sites were identified, i.e., between Ser5 and Tyr6 and between Asn18 and Arg19. Other modifications include providing a positive charge at, or near, the native amino terminus, and inserting unnatural, glycosylated or D- amino acid residues to the – and C-termini to improve stability in serum. Still other modifications to the pyrrhocoricin are cyclizing the

peptide to prevent cleavage by exopeptidases. Replacing conventional amide bonds between one or more amino acids in the sequence with bonds less sensitive to cleavage by proteases, e.g., thioamide bonds or reduced amide bonds, is also a desirable modification. Such a modification of bonds can desirably occur between Ser5 and Tyr 6 or between Asn18 and Arg19, or at both sites. Still other sites in the sequence may be so modified.

The native unmodified pyrrococorin contains on the 11th amino acid residue Thr of pyrrococorin, the sugar, galactose (Gal) -2-acetamido-2-deoxy-galactose (GalNAc), as follows:

Gal-GalNAc
1 5 10 | 15
Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-
20
Asn [SEQ ID NO: 2]. For use in the following assays, native pyrrhocoricin is referred to as Peptide 2.

The modifications of the de-glycosylated (non-native) pyrrocoricin amino acid sequences which provide peptides of this invention as well as control (inactive) peptides, appear in the sequences below in bolded, italicized print for ease of review. These peptides are identified by the following peptide numbers throughout the examples. In the modified peptides 1, and 3-25 below, all amino acids were of the L-configuration, except for peptides 12 and 13, in which the indicated amino acids were of the D-configuration. All carbohydrates were of the D-configuration. The following peptides are modified versions of pyrrocoricin, of which Peptides 1, 3-6, 8-12, and 17-24 are novel anti-bacterial peptides of this invention; and Peptides 7, 13-16 and 25 are modified inactive peptides shown for comparative purposes.

Active, modified Peptide 1 is a pyrrolicorin which is deleted in the naturally occurring mid-chain glycosylation, but which has the following 20 amino acid sequence:

Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [SEQ ID NO: 6].

Active, modified Peptide 3 has the sequence:

Acetyl-Lys-Val-Asp-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [SEQ ID NO: 7].

Active, modified Peptide 4 has the sequence:

5 *Acetyl-Arg-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn* [SEQ ID NO: 8].

Active, modified Peptide 5 has the sequence:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [SEQ ID NO: 9].

10 In the active, modified Peptide 6, the R¹ moiety is 1-aminocyclo-hexane carboxylic acid. The sequence is



[SEQ ID NO:10].

Inactive Peptide 7 is acetylated on its N-terminus and retains the galactose-2-acetamido-2-deoxy-galactose (Gal-GalNAc) modifying the 11th amino acid of native pyrrocoricin. The sequence is:

15

Gal-GalNAc

/

Acetyl-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [SEQ ID NO:11].

20

Active, modified Peptide 8 has the positively charged N-terminal acetyl-lysine group, and a C-terminal imide group which cyclizes the 20th amino acid residue and has the sequence [SEQ ID NO:12]:



Active, modified Peptide 9 has a positively charged N-terminal acetyl-Lysine and a β -acetyl-2,3-diamino propionic acid group (DapAc) in the L configuration attached to the 19th amino acid residue with the 20th amino acid residue eliminated.

The sequence is:

5 *Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-NH-CH-CONH₂* [SEQ ID NO: 13].



10 Active, modified Peptide 10 has a positively charged N-terminal acetyl-Lysine and a 2-acetamido-2-deoxyglucose (GlcNAc) group modifying the 20th amino acid residue on the C-terminus. The sequence is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [SEQ ID NO:14].

15 $\begin{array}{c} / \\ \text{GlcNAc} \end{array}$

Active, modified Peptide 11 has an N-terminal acetyl-Lysine and a triacetyl-2-acetamido-2-deoxyglucose (Ac3-GlcNAc) group modifying the 20th amino acid residue on the C-terminus. The sequence is:

20 *Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn* [SEQ ID NO:15].



25 Peptide 12 is a somewhat active modified peptide having the first amino acid residue Val in the D configuration, and the 20 amino acid Asn in the D configuration, with the sequence:

D-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-D-Asn [SEQ ID NO:16].


Inactive Peptide 13 is a pyrrococorin without the midchain glycosylation and with all amino acid residues in the D configuration:

30 *Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn* [SEQ ID NO:26].

Inactive Peptides 14 and 15 are 9 and 11 amino acid fragments, respectively, of pyrrhocoricin, having the sequences:


Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg [amino acids 1-9 of SEQ ID NO: 6] and
 5 Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn [amino acids 10-20 of SEQ ID NO:
 6, deleted of glycosylation].

Inactive Peptide 16 is a cyclic peptide in which the spacer is an additional Lys-Val dipeptide residue joining the N-terminal amino acid to the negatively charged (pre-cyclization) C- terminal amino acid. This spacer restricts the structure of the peptide. This peptide has the sequence as follows:



10 [SEQ ID NO:17].

The most active of the peptides of this invention is modified Peptide 17, which is a cyclic non-glycosylated peptide. In this peptide, a lysine residue was added to the amino terminus of the peptide, which is cyclized with an 8 residue spacer between the original N- and C-termini. The spacer corresponds to the middle domain (amino acid
 15 residues 7-14) of pyrrhocoricin and is incorporated backwards to remain in register with the original copy of this fragment. This arrangement retained with native orientation of the bioactive domains, i.e., the original termini. This peptide has the sequence as follows:



[SEQ ID NO:18].

Active, modified Peptide 18 has a positively charged biotin-Lys-Val group attached at the N-terminus, and having the sequence:

Biotin-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-Asn- [SEQ ID NO:19].

Active modified Peptide 19 has a positively charged group with a reporter sequence attached at the N-terminus, and having the sequence:

5(6)-carboxyfluorescein-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-
Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn- [SEQ ID NO:20].

Weakly active, modified Peptide 20 has the positively charged Acetyl-Lys-Val attached at the N-terminus, and replaces the C-terminal Asparagine with Aspartic acid. The sequence is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-Asp- [SEQ ID NO:21].

Active, modified Peptide 21 has an R¹ group of 1-aminocyclo-hexane carboxylic acid, and having attached at the C-terminus in place of the 19th amino acid Asn, a β-acetyl-2,3-diamino propionic acid group in the L configuration. The sequence is:




[SEQ ID NO: 22].

The active, modified Peptide 22 has an Acetyl-Arg group attached to the N-terminal Val, and having attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration. The sequence is:

Acetyl-Arg-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-NH-CH-CONH₂ [SEQ ID NO:23].

$$\begin{array}{c} / \\ \text{CH}_2\text{-NH-COCH}_3 \end{array}$$

Inactive Peptide 23 has the R¹ group 1-aminocyclo-hexane carboxylic acid, and replaces Ser5 and Tyr6 with Ala5 and Phe6. Attached at the C-terminus in place of the 19th amino acid Asn is a β -acetyl-2,3-diamino propionic acid group in the L configuration. The sequence is [SEQ ID NO:24]:



Active Peptide 24 has attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration:

Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-NH-CH-CONH₂ [SEQ ID NO:25].

$$\begin{array}{c} / \\ \text{CH}_2\text{-NH-COCH}_3 \end{array}$$

Inactive Peptide 25 is a fragment of pyrrocoricin having the sequence:
Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn [amino acids 1-18 of SEQ ID NO: 6].

These peptides are tested in some or all of the following assays of Examples 2-4 below.

EXAMPLE 2: *IN VITRO* ANTI-BACTERIAL ACTIVITY OF THE PEPTIDES

Growth inhibition assays were performed using the peptides of Example 1 and the Gram positive microorganisms *Micrococcus luteus* and *Bacillus megaterium*, and

the Gram negative microorganisms, *Escherichia coli* D22, *Agrobacterium tumefaciens*, and *Salmonella typhimurium*. Anti-bacterial assays were performed in sterilized 96-well plates (Nunc F96 microtiter plates) with a final volume of 100 μ l as described in Bulet (1996), cited above. Briefly, 90 μ l of a suspension of a
5 midlogarithmic phase bacterial culture at an initial 600 nm UV absorbance of 0.001 in Luria-Bertani rich nutrient medium was added to 10 μ l of serially diluted peptides in sterilized water. The final peptide concentrations ranged between 0.15 and 80 μ M. The plates were incubated at 30°C for 24 hours with gentle shaking, and the growth inhibition was measured by recording the increase of the UV absorbance at 600 nm on
10 an SLT Labinstruments 400 ATC microplate reader. The experiments were conducted over a 7-month period.

Table 1 reports the inhibitory concentrations (IC_{50}) of each peptide #1 to #25 [SEQ ID NOS: 2 and 6-26] identified in Example 1 against each above-indicated microorganism. IC_{50} is defined as the concentration in μ M at which 50% growth
15 inhibition of the indicated microorganism is observed. To assess the variability of the assay, Peptide 22 [SEQ ID NO: 23] was reassayed after 3 months of the original date, and both the original (a) and 3 month (b) results are reported in the table. No activity up to 80 μ M concentration is indicated by "-"; an IC_{50} greater than 10 is essentially evidence of an inactive peptide.

#	TABLE I: IC ₅₀ in μ M against				
	<i>Micrococcus luteus</i>	<i>Bacillus megaterium</i>	<i>Escherichia coli</i> D22	<i>Agrobacterium tumefaciens</i>	<i>Salmonella typhimurium</i>
1	10	5	<0.075	<0.075	0.6
2	-	40	0.3	0.3	2.5
3	80	-	0.3	10	5
4	5	-	0.6	2.5	2.5
5	40	-	0.6	5	40
6	5	10	0.3	1.25	2.5
7	-	-	10	-	-
8	5	20	0.3	1.25	2.5
9	10	40	0.6	1.25	1.25
10	40	-	0.6	5	2.5
11	40	40	0.6	2.5	20
12	10	-	0.6	2.5	5
13	40	-	-	-	-
14	-	-	-	-	-
15	-	-	-	-	-
16	-	-	-	-	-
17	0.6	2.5	0.6	2.5	5
18	5	-	<0.15	1.25	1.25
19	80	-	5	20	40
20	-	-	2.5	40	-
21	10	40	0.6	5	2.5
22 a/b	10/10	40/80	0.3/0.3	2.5/0.6	2.5/2.5
23	5	40	20	-	-
24	5	20	<0.3	<0.3	<0.3
25	-	-	-	-	-

The two putative binding sites cannot be separated (see, Peptides 14 and 15) [aa 1-9 and aa 10-20, respectively of SEQ ID NO: 6]. An equimolar mixture of shorter Peptides 14 and 15 remained inactive in all five bacterial strains studied. An analog made of only D-amino acids was similarly inactive (Peptide 13) [SEQ ID NO: 26], indicating that pyrrocoricin binds stereospecifically to a target protein. The N-terminus of the native glycopeptide (Peptide 7) [SEQ ID NO: 11] could not be blocked without a major loss of anti-bacterial activity. Pyrrocoricin analogs containing labels and an additional lysine at the N-terminus (Peptides 18 and 19) [SEQ ID NOS: 19 and 20] retain biological activity.

The results in Table 1 demonstrate several additional characteristics of the modified peptides of this invention vs. the unmodified Peptides 1 and 2 [SEQ ID NO: 6 and 2, respectively]. The differences in the IC_{50} values between the results for Peptide 22 [SEQ ID NO: 23] in two performances of the assay (at time a and 3 months later at time b) demonstrate the variability of the assays. In general, modifications at either termini reduced the potency of unmodified pyrrocoricin. From the N- or C-terminally modified peptides, the modifications of a 1-aminocyclo-hexane carboxylic acid at the amino terminus and a β -acetyl-2,3-diamino propionic acid group at the carboxy-terminus retained most of the anti-bacterial activity. In a preferred embodiment for drug development, both termini are modified to block or at least retard exopeptidase cleavage. Peptides containing modifications at both termini featured acetylation together with positively charged amino acid addition, incorporation of unnatural amino acids, such as Chex or Dap(Ac), glycosylation, imide formation, D-amino acid substitution or cyclization. Examples of desirable peptides having modifications at both termini are Peptides # 8, 9, 10, 11, 12, 13, 16, 17, 21, and 22 [SEQ ID NOS: 12-16, 26, 17, 18, 22 and 23, respectively].

Considering the time of the assay and the requirement for submicromolar activity against at least one strain, Peptide 1 [SEQ ID NO: 6], Peptide 17 [SEQ ID NO: 18], Peptide 21 [SEQ ID NO: 22] and Peptide 22 [SEQ ID NO: 23], described above in Example 1 were selected for further studies, which include normal cell toxicity and serum stability assays followed by *in vivo* efficacy studies. These peptides

show remarkable activity against Gram negative bacteria. The best analog for killing Gram-negative and Gram-positive bacteria (e.g., wide spectrum activity) is cyclic Peptide 17, which demonstrated a broad activity spectrum at low micromolar concentrations.

5 EXAMPLE 3: ASSAYS FOR TOXICITY TO MAMMALIAN CELLS

 A. *Hemolytic Activity*

 To determine whether native and modified pyrrolicorin peptides were toxic to mammalian cells, several peptides from Example 1 above, a positive control, and a negative control were examined for hemolytic activity. Hemolytic activity was
10 assayed with sheep erythrocytes suspended in Alsever's solution (BioWhittaker, Walkersville, MD), and diluted with Dulbecco's phosphate-buffered saline, pH 7.2. Thirty μ L of a 1% suspension of the red blood cells was incubated with agitation at 39°C with 30 μ L of 40 to 256 μ M of each of the following peptides dissolved in phosphate buffered saline for one hour and centrifuged at 1000 g for five minutes.
15 Fifty μ L of the supernatant was collected and the release of hemoglobin was detected by measuring the ultraviolet absorbences of triplicate samples of the 40 μ M or 256 μ M test peptides and the control peptides at 405 nm.

 The peptides tested in this assay were Peptide 1, Peptide 21, Peptide 22, and Peptide 23 [SEQ ID NOS: 6, 22, 23 and 24, respectively] from Example 1.
20 The positive control was melittin, which has the sequence:
Gly-Ile-Gly-Ala-Val-Leu-Lys-Val-Leu-Thr-Thr-Gly-Leu-Pro-Ala-Leu-Ile-Ser-Trp-Ile-Lys-Arg-Lys-Arg-Gln-Gln-amide (Bachem, King of Prussia, PA) [SEQ ID NO:27].
The negative control was peptide 31D, a T helper cell epitope [Ertl *et al*, *J. Virol.*, 63:2885-2892 (1989)] having the sequence: Ala-Val-Tyr-Thr-Arg-Ile-Met-Met-Asn-
25 Gly-Gly-Arg-Leu-Lys-Arg-amide [SEQ ID NO:28]. The results of this assay are reported below in Table 2.

Table 2

Peptide #	Absorbance at 405 nm	
	40 μ M	256 μ M
1	0.108 \pm 0.015	0.0135 \pm 0.005
21	0.110 \pm 0.049	0.143 \pm 0.006
22	0.126 \pm 0.019	--
23	0.118 \pm 0.035	--
Melittin (positive control)	2.99 \pm 0.06	--
31D (negative control)	0.160 \pm 0.021	--

At a final concentration of 40 μ M, only melittin lysed the erythrocytes. The lowest concentration in which melittin lysed sheep erythrocytes was 5 μ M, in agreement with the findings of Wade *et al*, Proc. Natl. Acad. Sci., USA, 87:4761-4765 (1990). When the pyrrhocoricin and the modified Chex-pyrrhocoricin-Dap(Ac) peptide were increased to 256 μ M concentration, the peptides remained completely non-toxic to sheep erythrocytes.

B. Direct Killing of Immortalized COS Cells

In another toxicity assay, COS cell survival was studied for pyrrhocoricin and cecropin B (Bachem Biosciences, King of Prussia, PA) as the positive control. Cecropin B was used as a positive control because this channel-forming anti-bacterial peptide was shown to kill a wide range of immortalized tumor cells [A. J. Moore *et al*, Peptide Res., 5:265-269 (1994)]. The results are indicated in Table 3.

Table 3

Peptide	Cell Count after Treatment
No peptide	13.5 ± 9.5
5 µM Cecropin	6 ± 6
10 µM Cecropin	6.7 ± 0.3
50 µM Cecropin	7.3 ± 3.7
5 µM Pyrrhocoricin	18 ± 4
10 µM Pyrrhocoricin	12 ± 4
50 µM Pyrrhocoricin	11 ± 1

While cecropin reduced the cell count at as low as 5 µM concentration, the cell count and rate of proliferation did not change after addition of up to 50 µM/mL concentration of pyrrhocoricin.

EXAMPLE 4: PEPTIDE STABILITY IN SERUM

In vivo stability of peptides in blood is currently modeled well by *in vitro* stability in serum or plasma (neglecting renal and hepatic clearance). Serum stability studies represent one of the most important secondary screening assays in peptide drug development, largely because they eliminate peptides that have short half-lives and are therefore unlikely to be therapeutically effective. Owing to the fact that the use of diluted serum increases peptide recovery as well as retards the reaction kinetics to a manageable rate, the experiments were conducted using 25% aqueous sera. It was earlier demonstrated that the degradation rates are linearly proportional to serum concentration [M. F. Powell *et al*, *J. Pharm. Sci.*, **81**: 731-735 (1992)].

For serum stability studies, 10 µl of an aqueous peptide stock solution containing about 0.8 mg/ml peptide was added to 200 µl 25% aqueous pooled mouse or human serum (Sigma, St. Louis, MO), according to the process described in M. F. Powell *et al*, *Pharmacol. Res.*, **10**:1268-1273 (1993). The peptide-serum mixture was thermostated at 37°C. After 0 minutes, 45 minutes, 2 hours and 4 hours, three

samples of each peptide were taken and precipitated by the addition of 40 μ l 15% aqueous trichloroacetic acid. The samples were stored at 4°C for 20 minutes and centrifuged. The peptides and some remaining serum proteins were recovered in the supernatant after the trichloroacetic acid precipitation. The supernatants were immediately frozen on dry-ice and 220 μ l of each were analyzed on RP-HPLC. A mouse serum and two different batches of the same SIGMA catalog number of human sera (human 1, approximately 1 year old, and human 2, approximately 1 month old) were also used.

To obtain comparable data, all peptide degradation at 0 minutes is adjusted to 100%. The lyophilized samples were redissolved in 0.1 aqueous TFA and submitted for matrix assisted laser desorption/ionization (MALDI-MS).

The degradation products of the modified peptides of this invention (Peptides 1, 21 and 22 [SEQ ID NOS: 6, 22 and 23, respectively]) after a 45-minute digestion with 25% mammalian sera are reported in Table 4. The missing residues are indicated (e.g. -C2 means that the C-terminal two residues are cleaved off). For Peptide 22 (which is a modified pyrrhocoricin, having an acetyl-Arg group attached to the N-terminal Val, and having attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration), the N-terminal residue numbers correspond to unmodified pyrrhocoricin. In Table 4, the relative amounts of the degradation products are estimated based on the MALDI-MS peak heights. 0=not detected; 1=very weak (below 5000), 2=weak (5-10000), 3=medium (10-15000), 4=strong (15000-uncleaved molecular ion at 25-30000), 5=very strong (above uncleaved molecular ion). All identified degradation products are listed.

Table 4

Pep tide #	Serum	Degradation Products							
		-C1	-C2	-C3	-C6	-N3	-N5	-N3, C2	-N5, C2
1	mouse	2	2	0	0	0	0	0	0
	human 1	3	4	3	1	0	2	0	0
	human 2	2	2	0	0	0	0	0	0
21	mouse	0	2	0	0	0	2	0	0
	human 1	0	4	2	0	0	2	0	1
	human 2	0	4	0	0	0	2	0	1
22	mouse	0	2	0	0	0	0	0	0
	human 1	0	5	3	0	2	3	1	2
	human 2	0	5	0	0	2	1	0	0

When looking at the first metabolites after 45 minute digestion, it is evident that the C-terminal asparagine is cleaved off Peptide 1 [SEQ ID NO: 6]. In contrast, the modified C-terminal residue stays on the peptides containing β -acetyl-2,3-diamino propionic acid residues (Peptides 21 and 22) [SEQ ID NOS: 22 and 23, respectively]. The acetyl-Arg amino terminal modified Peptide 22 produces more N-terminal cleavage products close to the amino terminus than Peptide 21 (which is a modified pyrrolicorcin, having in place of the N-terminal Val, the group 1-aminocyclo-hexane carboxylic acid-, and having attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration). Most notably, Peptide 21 produces a fragment in which the Val-Asp-Lys tripeptide is missing. While for Peptide 1 the degradation products are different in the two human sera, for Peptide 21, they are very similar. They are also similar to those observed after digestion with the mouse serum. Apparently, Peptide 21, is generally more resistant than Peptide 1 in human serum.

Fig. 1 shows the kinetics of the degradation of Peptides 1 and 21 [SEQ ID NOS: 6 and 22, respectively] in this assay. The curves are fitted to an exponential equation. The degradation curves for Peptide 1 and Peptide 21 (the modified pyrrhocorin, having in place of the N-terminal Val, the group 1-aminocyclo-hexane carboxylic acid-, and having attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration) were similar. Nonglycosylated pyrrhocorin is somewhat more stable in mouse serum and in the weaker human serum, but much less stable in the more active human serum. Although the lack of endopeptidase cleavage sites reduced the degradation rate of Peptide 21 compared to Peptide 1, this loss of protease activity was compensated for increased exopeptidase activity C-terminal to Ser5 and Asn18. Preliminary metabolism studies of the cyclic Peptide 17 [SEQ ID NO: 18] indicated an endopeptidase cleavage site between Asn18 and Arg19 in human sera. In accordance with the increased number and amount of N-terminal degradation products, Peptide 22 [SEQ ID NO: 23] (a modified pyrrhocorin, having an acetyl-Arg group attached to the N-terminal Val, and having attached at the C-terminus in place of the 20th amino acid Asn, a β -acetyl-2,3-diamino propionic acid group in the L configuration), degrades considerably faster than either Peptide 1 or Peptide 21 (not shown). Remarkably, after 8 hours of digestion, in mouse serum, both Peptides 1 and 21 have 20% of the initial amounts intact. Significantly, after the same period of time, traces of Peptide 21 are still present in all sera studied.

EXAMPLE 5 - *IN VIVO* Anti-bacterial ACTIVITY OF THE PEPTIDES

Peptides 1, 17 and 21 [SEQ ID NOS: 6, 18, and 22, respectively] are comparatively evaluated in an *in vivo* anti-bacterial assay performed as follows: Male mice of CD-1 strain (Harlan Sprague Dawley, Inc.) were intravenously infected in the tail with 1,000,000 colony forming units (0.2 ml) of *Escherichia coli* strain (ATCC Accession No. 25922). To obtain better infection, mice are also fed with *E. coli*. The test peptides are intravenously injected 1 hour after infection at doses of 10, 25 and 50 mg/kg, followed by a booster injection after 5 hours of infection. Mice were observed

at 1 hour, 5 hours, 1 day, and 2 days post-infection for clinical signs (e.g., decreased activity and head tilt) or mortality, and were compared with control mice who received 5% dextrose (DS5) instead of peptides (negative control) or were submitted to the same peptide treatment, but received 50 mg/kg of DS5 instead of the bacteria (toxicity).

The results are illustrated in Fig. 2. Neither Peptides 1 nor 21 [SEQ ID NOS: 6 and 22, respectively] alone showed any toxicity at 50 mg/kg dose. To assess the success of the infection, five mice were infected with *E. coli*, but received DS5 instead of test peptides. Two of these control mice died on the third day and the other three became clinically sick, which included decreased activity and head tilt. When the efficacy of the peptides was studied, the Chex-pyrrhocoricin-Dap(Ac) derivative (Peptide 21) protected all 15 mice, regardless of the dose. For unmodified pyrrhocoricin (Peptide 1), the mice that were injected with 10 and 25 mg/kg survived without any clinical signs of disease. However, from the 50 mg/kg group, one mouse died and the other 4 showed clinical signs of disease. This mirrors the drosocin studies in which the peptide was not toxic alone, but became toxic when the mice were infected and became compromised [Hoffmann *et al*, cited above].

Such an effect was not found for the Chex-pyrrhocoricin-Dap(Ac) peptide. All mice showed some enlargement of the abdominal region during the study, therefore at termination the mice were necropsied. Stomachs and intestines were observed to be enlarged due to the presence of food. There were no other findings. These data indicate that the increase of the proteolytic stability of the pyrrhocoricin peptides compared to drosocin resulted in peptides capable of protecting mice against bacterial infection. The results also warrant further pharmaceutical development with peptides based on Peptide 21 [SEQ ID NO: 22], the Chex-pyrrhocoricin-Dap(Ac) peptide. This analog showed good potency, complete lack of toxicity and similarity in the degradation pathway between human and mouse serum.

EXAMPLE 6 - CONFORMATION OF NATIVE PYRRHOCORICIN.

Because native pyrrhocoricin could not be shortened nor could the amino acid composition be changed without a loss of *in vitro* anti-bacterial activity, it was theorized that the peptide has to assume a certain secondary structure to bind stereospecifically to the target protein. Clearly, this structure is desirably maintained in the design of potential drugs. The bioactive conformations of native glycosylated pyrrhocoricin (Peptide 2) [SEQ ID NO: 2] and its non-glycosylated analog (Peptide 1) [SEQ ID NO: 6] were determined by two-dimensional nuclear magnetic resonance (NMR) spectroscopy.

¹H NMR spectra were recorded on a Bruker DMX 750 MHz spectrometer at temperatures in the range 283-298° K. The sample consisted of ≈ 600 μg of native glycosylated or non-glycosylated pyrrhocoricin in 125 μL of 50% TFE-d₃:50% H₂O solution in a 2.5 mm NMR tube. Two-dimensional TOCSY and NOESY spectra were recorded in the phase sensitive mode using time proportional phase incrementation for quadrature detection in the f1-dimension [D. Marion and K. Wüthrich, Biochem. Biophys. Res. Comm., **113**: 967-974 (1983)]. TOCSY spectra were recorded using an MLEV-17 mixing scheme [A. Bax and D. G. Davis, J. Mag. Res., **65**:355-360 (1985)] with a mixing times of 80 ms, 16 scans and 512 increments. NOESY spectra were recorded with mixing times of 100 and 300 ms, 64 scans and 512 increments. All 2D spectra were collected over 4096 data points in the f2 dimension, with a spectral width of 9800 Hz in both dimensions. The water proton signal was suppressed using the WATERGATE method, consisting of two sine-shaped gradient pulses on either side of a binomial 3-9-19 pulse of 10 kHz field strength. Spectra were referenced to DSS. The data were processed on a Silicon Graphics (SGI 4D/30) computer using the UXNMR software package. The f1-dimension was zero-filled to 4096 real data points with f1- and f2-dimensions being multiplied by a squared sine function and Gaussian function, respectively, prior to Fourier transformation.

Like the recently published conformation of drosocin [A. McManus et al, cited above], the structure of pyrrhocoricin was largely random coil and there was little change in the backbone conformation upon glycosylation. For pyrrhocoricin, however,

there was a subpopulation with organized structure at both the N- and C-termini. Figs. 3A and 3B summarize the short and medium-range NOEs and show that there were a series of $d_{NN(i,i+1)}$ NOEs present at both the N- and C-termini of the pyrrhocoricins. Additional $d_{\alpha N(i,i+2)}$ NOEs were found in the spectra of the glycosylated derivative.

5 Taken together, the data indicated the presence of reverse-turns at the pharmacologically important terminal regions. The increase in the turn potential at the termini compared to drosocin may explain the increased *in vitro* anti-bacterial activity of pyrrhocoricin. A comparison of the α H NMR shifts with random coil values [Merutka *et al*, *J. Biomol. NMR*, 5:14-24 (1995)] is shown in Fig. 3C. These results
10 suggested that the middle domain of pyrrhocoricin, like drosocin, had an extended structure. Both the unordered-turn conformational equilibrium and the presence of extended regions were further verified by CD spectroscopy (data not shown). Non-glycosylated pyrrhocoricin (Peptide 1) [SEQ ID NO: 6] exhibited a linear unordered \rightarrow reverse turn conformational transition upon going from water to trifluoroethanol as
15 solvents. The CD spectrum of the native glycopeptide recorded in water was more similar to those of unordered peptides (type U spectra). However, the type C spectrum, and therefore the final turn structure was stabilized at a lower trifluoroethanol concentration (50%) for the glycopeptide compared to the non-glycosylated analog, fully supporting the NMR findings. The broadening of the
20 negative band between 210 and 220 nm in the aqueous spectra identified the presence of extended structures for both peptides.

In summary, according to the NMR data the bioactive conformation of pyrrhocoricin involves two reverse-turns at the termini bridged by an extended peptide segment in the middle domain. This hypothetical structure is supported by the anti-
25 bacterial activity of the cyclic peptide analogs. Cyclization stabilizes reverse-turns, and was expected to improve potency, but the cyclic pyrrhocoricin derivative without expanding the cycle (Peptide 16) [SEQ ID NO: 17] lost activity compared to the analog linear peptide (Peptide 20) [SEQ ID NO: 21], probably due to distortion of the extended domain in the middle of the peptide. When the ring size was increased by
30 repeating an internal octapeptide fragment (Peptide 17) [SEQ ID NO: 18], the

resulting cyclic analog became highly active against both gram-negative and gram-positive bacterial strains.

5 All documents cited above are incorporated by reference herein. This invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. The disclosures of the patents, patent applications and publications cited herein are incorporated by reference in their entirety.

WHAT IS CLAIMED IS:

1. A peptide of the formula R^1 -Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'- R^2 SEQ ID NO: 1,

wherein R^1 is a moiety having a net positive charge;

wherein R^2 is selected from the group consisting of a free hydroxyl, an amide, an imide, a sugar, and a sequence of one or up to about 15 additional amino acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar, said additional amino acids being independently selected from L-configuration or D-configuration and said additional amino acids capable of cyclizing the peptide by bridging between the N- and C- termini thereof;

wherein X and Y form a dipeptide selected from the group consisting of Ser-Tyr and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage; and

wherein X' and Y' form a dipeptide selected from the group consisting of Asn-Arg, and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage

2. The peptide according to claim 1, wherein R^1 is selected from the group consisting of (a) a straight chain, branched, cyclic or heterocyclic alkyl group, (b) a straight chain, branched, cyclic or heterocyclic alkanoyl group, (c) a positively charged reporter group; and (d) between 1 to 15 additional amino acids independently selected from L-configuration or D-configuration; said additional amino acids optionally substituted by one or more of (a), (b) or (c), and said additional amino acids capable of cyclizing the peptide by bridging between the N- and C- termini thereof.

3. The peptide according to claim 2, wherein said R^1 group (d) are amino acids which have been cyclized by the insertion into the structure of the amino acid of modifying sugars or imide.
4. The peptide according to claim 2, wherein said R^1 group (a) is 1-aminocyclo-hexane carboxylic acid.
5. The peptide according to claim 2, wherein said R^1 group (d) is selected from the additional amino acid residues L-Val-, D-Val-, Arg-Val-, Lys-Val-, Lys-Val-Asp-Lys-Val- SEQ ID NO: 5, and -Arg-Pro-Pro-Thr-Pro-Arg-Pro-Leu-Lys-Val- SEQ ID NO: 3.
6. The peptide according to claim 1, wherein said R^1 group is selected from Acetyl-Arg-Val-; Acetyl-Lys-Val-; and Acetyl-Lys-Val-Asp-Lys-Val- SEQ ID NO: 29.
7. The peptide according to claim 2, wherein said R^1 group (c) is biotin.
8. The peptide according to claim 2 wherein said R^1 group provides a detectable signal, optionally upon interaction with other compounds.
9. The peptide according to claim 8 wherein said R^1 group (c) is 5(6) carboxyfluorescein.
10. The peptide according to claim 2 wherein R^1 group (c) is radioactive.
11. The peptide according to claim 2 wherein R^1 group (d) is a spacer interposed between the N- terminus and C- terminus of said peptide, permitting cyclization of said peptide.

12. The peptide according to claim 11, wherein R^1 group (d) is -Arg-Pro-Pro-Thr-Pro-Arg-Pro-Leu-Lys-Val- SEQ ID NO: 3, said Val linked to the N-terminal Asp of said formula and the N-terminal amino acid of R^1 linked by a covalent bond to the C-terminal amino acid of R^2 .

13. The peptide according to claim 1, wherein R^2 is selected from the group consisting of D-Asn, L-Asn, Asp, and Asn- R^3 , wherein R^3 is a sugar.

14. The peptide according to claim 1, wherein said R^2 is an amino acid can cyclize the peptide by attaching to the amino terminal amino acid.

15. The peptide according to claim 13 wherein R^3 is selected from the group consisting of 2-acetamido-2-deoxyglucose and triacetyl 2-acetamido-2-deoxyglucose.

16. The peptide according to claim 1, wherein R^2 is a β -acetyl-2,3-diamino propionic acid group.

17. The peptide according to claim 1, wherein at least one amino acid is altered to its corresponding D amino acid.

18. The peptide according to claim 1, which is non-glycosylated.

19. The peptide according to claim 1, which is a cyclic peptide in which R^1 and/or R^2 form an amino acid spacer of greater than 3 amino acid residues.

20. The peptide according to claim 19, wherein said spacer duplicates at least a portion of the peptide sequence of claim 1.

21. The peptide according to claim 1, which is:

Val-Asp-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO:30.

22. The peptide according to claim 1, which is:

Acetyl-Lys-Val-Asp-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO: 7.


23. The peptide according to claim 1, which is :

Acetyl-Arg-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO:8.

24. The peptide according to claim 1, which is:


Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO: 9.

25. The peptide according to claim 1, which is:



SEQ ID NO:10.

26. The peptide according to claim 1, which is:



SEQ ID NO: 12.

27. The peptide according to claim 1, which is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-NH-CH-CONH₂ SEQ ID NO: 13.
|
CH₃-NH-COCH₃

28. The peptide according to claim 1, which is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-Asn SEQ ID NO: 14.
|
2-acetamido-2-deoxyglucose

29. The peptide according to claim 1, which is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-Asn SEQ ID NO:15.
|
triacetyl-2-acetamido-2-deoxyglucose

30. The peptide according to claim 1, which is

D-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-D-Asn SEQ ID NO: 16.

31. The peptide according to claim 1, which is:

Biotin-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO:19.

32. The peptide according to claim 1, which is:

5(6)-carboxyfluorescein-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-Asn SEQ ID NO: 20.

33. The peptide according to claim 1, which is:

Acetyl-Lys-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-
Tyr-Asn-Arg-Asp SEQ ID NO: 21.

34. The peptide according to claim 1, which is:



SEQ ID NO: 22.

35. The peptide according to claim 1, which is:

Acetyl-Arg-Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-NH-CH-CONH₂ SEQ ID NO: 23.




36. The peptide according to claim 1, which is:

Val-Asp-Lys-Gly-Ser-Tyr-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-Asn-Arg-NH-CH-CONH₂ SEQ ID NO: 25.



37. The peptide according to claim 18, which is:



SEQ ID NO: 18.

38. The peptide according to any of claims 1-37 which has metabolic stability in mammalian serum.

39. The peptide according to claim 1 wherein at least one conventional amide bond between two amino acids in said sequence is replaced with a non-cleavable bond.

40. The peptide according to claim 39, wherein said non-cleavable bond is a thio-amide bond or a reduced amide bond.

41. A composition comprising multiple peptides of the formula
 $R^1\text{-Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'-R}^2$ SEQ
ID NO:1,

wherein R^1 is a moiety having a net positive charge;

wherein R^2 is selected from the group consisting of a free hydroxyl, an amide, an imide, a sugar, and a sequence of one or up to about 5 additional amino acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar, said additional amino acids being independently selected from L-configuration or D-configuration and said additional amino acids capable of cyclizing the peptide by bridging between the – and C- termini thereof;

wherein X and Y form a dipeptide selected from the group consisting of Ser-Tyr and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage,

wherein X' and Y' form a dipeptide selected from the group consisting of Asn-Arg, and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage.

42. The composition according to claim 41, comprising at least two peptides, wherein the second peptide is attached to any amino acid of the first peptide.

43. The composition according to claim 42, wherein additional peptides are attached to any amino acid of the other peptides in the composition.

44. The composition according to claim 41, comprising at least two said peptides, wherein at least one or more of said peptides is attached to a carrier.

45. The composition according to claim 41, comprising at least two peptides of claim 1, wherein the second or additional peptides is attached to a branched construct of the other peptides in the composition.


46. The composition according to claim 41, comprising at least two peptides of claim 1, wherein each additional peptide is covalently linked to R² of another peptide in the composition.

47. The composition according to claim 41, which comprises a multiple antigenic peptide.

48. The composition according to claim 47, wherein said multiple antigenic peptide comprises a β -alanine substituent on a poly-lysine core.

49. The composition according to claim 47, comprising at least four peptides.

50. The composition according to claim 49, comprising the structure




wherein each said peptide is:



SEQ ID NO: 10.

51. The composition according to claim 41, comprising the multi-peptide
SEO ID NO: 4 construct



52. The composition according to claim 41 wherein said peptide is produced synthetically.

53. The composition according to claim 41 wherein said peptide is produced recombinantly.

54. The composition according to claim 41 wherein one or more of said peptides is a synthetic peptide fused to a second moiety, wherein said moiety enhances the bioavailability of said peptide.

55. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a peptide of claim 1 or multi-peptide composition of claim 41 in operative association with a regulatory sequence directing the expression thereof in a host cell.

56. A host cell transfected or transformed with the molecule of claim 55.

57. A pharmaceutical composition comprising one or more of the peptides of claim 1 or the compositions of claim 41, in a pharmaceutically acceptable carrier.

58. A method of treating a mammalian infection comprising administering to a mammal having said infection an effective amount of a composition of claim 57.

59. The method according to claim 58, wherein said infection is a bacterial infection.

60. The method according to claim 58 wherein said infection is caused by a Gram negative bacterium.

61. The method according to claim 58 wherein said infection is caused by a Gram positive bacterium.

62. The method according to claim 58, wherein said infection is a fungal infection.

63. The method according to claim 58 wherein said composition is administered by a route selected from intravenous, oral, intradermal, transdermal, intraperitoneal, intramuscular, subcutaneous, by inhalation and mucosal.

64. A method of treating a mammalian infection comprising administering to a mammal having said infection a low dose of a pharmaceutical composition comprising deglycosylated pyrrolicorin.

65. The method according to claim 64, wherein said infection is a bacterial infection.

66. The method according to claim 64, wherein said infection is a fungal infection.

67. The method according to claim 64, wherein said low dose is less than 10 mg/kg patient body weight.

68. A method for designing pharmaceutical compounds comprising:
employing a peptide of claim 1 or a composition of claim 41 in a computer modeling program to design a compound which mimics the structure and biological effect of said peptide or composition.

69. The method for identifying pharmaceutical compounds comprising:
performing a competitive assay with a microorganism susceptible to a peptide of claim 1 or a composition of claim 41; a peptide of claim 1 or a composition of claim 41, and at least one test compound; and
identifying said test compound which competitively displaces the binding of said peptide or said composition to a receptor on said microorganism.

70. The method according to claim 69, wherein said microorganism is a bacterium.

71. The method according to claim 69, wherein said microorganism is a fungus.

72. A compound produced or identified by the method of claim 68 or 69.




Fig. 1

2/3




Fig. 2

Fig. 3B




Fig. 3A




Fig. 3C

SEQUENCE LISTING

- <110> The Wistar Institute of Anatomy and Biology
Otvos Jr., Laszlo
- <120> Novel Pyrrhocoricin-Derived Peptides, and Methods of
Use Thereof
- <130> WST91BPCT
- <140>
<141>
- <150> 60/140,606
<151> 1999-06-23
- <150> 60/154,135
<151> 1999-09-15
- <160> 30
- <170> PatentIn Ver. 2.1
- <210> 1
<211> 18
<212> PRT
<213> Artificial Sequence
- <220>
<221> MOD_RES
<222> (1)
<223> Asp in position 1 is attached to one or more
modified amino acids or to a chemical group
- <220>
<221> MOD_RES
<222> (4)
<223> amino acid in position 4 can be Ser or any amino
acid
- <220>
<221> MOD_RES
<222> (5)
<223> amino acid in position 5 can be Tyr or any amino
acid
- <220>
<221> MOD_RES

<222> (17)

<223> amino acid in position 17 can be Asn or any amino acid

<220>

<221> MOD_RES

<222> (18)

<223> amino acid in position 18 can be Arg or any amino acid and is attached to one or more modified amino acids or to a chemical group

<220>

<223> Description of Artificial Sequence: modification of Pyrrhocoricin

<400> 1

Asp Lys Gly Xaa Xaa Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr
1 5 10 15

Xaa Xaa

<210> 2

<211> 20

<212> PRT

<213> Pyrrhocoricin

<220>

<221> MOD_RES

<222> (11)

<223> Thr in position 11 is modified with Gal-GalNAc

<400> 2

Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15

Tyr Asn Arg Asn

20

<210> 3

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: modification

of Pyrrhocoricin

<400> 3

Arg Pro Pro Thr Pro Arg Pro Leu Lys Val
1 5 10

<210> 4

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Asp in position 1 is modified by a
1-aminocyclo-hexane carboxylic acid

<220>

<221> MOD_RES

<222> (18)

<223> Arg in position 18 is modified by an amino linker
moiety

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 4

Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr
1 5 10 15

Asn Arg

<210> 5

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 5

Lys Val Asp Lys Val
1 5

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 6
Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15

Tyr Asn Arg Asn
20

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLTATION

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 7
Lys Val Asp Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro
1 5 10 15

Pro Arg Pro Ile Tyr Asn Arg Asn
20

<210> 8
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin.

<400> 8

Arg	Val	Asp	Lys	Gly	Ser	Tyr	Leu	Pro	Arg	Pro	Thr	Pro	Pro	Arg	Pro
1				5				10					15		

Ile Tyr Asn Arg Asn
20

<210> 9

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 9

Lys	Val	Asp	Lys	Gly	Ser	Tyr	Leu	Pro	Arg	Pro	Thr	Pro	Pro	Arg	Pro
1				5				10					15		

Ile Tyr Asn Arg Asn
20

<210> 10

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Asp in position 1 is modified by a
1-aminocyclo-hexane carboxylic acid

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 10

Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr
1 5 10 15

Asn Arg Asn

<210> 11

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (11)

<223> Thr in position 11 is modified with Gal-GalNAC

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 11

Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15

Tyr Asn Arg Asn

20

<210> 12

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (20)

<223> Arg in position 20 is modified by an imide group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 12

Lys	Val	Asp	Lys	Gly	Ser	Tyr	Leu	Pro	Arg	Pro	Thr	Pro	Pro	Arg	Pro
1				5				10						15	

Ile	Tyr	Asn	Arg
			20

<210> 13

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (20)

<223> Arg in position 20 is modified by a
beta-acetyl-2,3-diamino propionic acid group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 13

Lys	Val	Asp	Lys	Gly	Ser	Tyr	Leu	Pro	Arg	Pro	Thr	Pro	Pro	Arg	Pro
1				5				10						15	

Ile	Tyr	Asn	Arg
			20

<210> 14

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (21)

<223> Asn in position 21 is modified by a
2-acetamido-2-deoxyglucose group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 14

Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg Asn
20

<210> 15

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (21)

<223> Asn in position 21 is modified by a
triacetyl-2-acetamido-2-deoxyglucose group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 15

Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro

1

5

10

15

Ile Tyr Asn Arg Asn
20

<210> 16

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Val in position 1 is in the D configuration

<220>

<221> MOD_RES

<222> (20)

<223> Asn in position 20 is in the D configuration

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 16

Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15

Tyr Asn Arg Asn
20

<210> 17

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(21)

<223> is a cyclic peptide

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 17

Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg Asp
20

<210> 18
<211> 29
<212> PRT
<213> Artificial Sequence

<220>
<221> PEPTIDE
<222> (1)..(29)
<223> is a cyclic peptide

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 18
Arg Pro Pro Thr Pro Arg Pro Leu Lys Val Asp Lys Gly Ser Tyr Leu
1 5 10 15

Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr Asn Arg Asn
20 25

<210> 19
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> Lys in position 1 has a biotin attached

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 19
Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg Asn

20

<210> 20
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> Lys in position 1 is modified by a
5(6)-carboxyfluorescein group

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 20
Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg Asn
20

<210> 21
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLTATION

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 21
Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg Asp
20

<210> 22
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> Asp in position 1 is modified by a
1-aminocyclo-hexane carboxylic acid group

<220>
<221> MOD_RES
<222> (18)
<223> Arg in position 18 is modified by a
beta-acetyl-2,3-diaminopropionic acid group

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 22
Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr
1 5 10 15

Asn Arg

<210> 23
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLATION

<220>
<221> MOD_RES
<222> (20)
<223> Arg in position 20 is modified by a
beta-acetyl-2,3-diamino propionic acid group

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 23

Arg Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro
1 5 10 15

Ile Tyr Asn Arg
20

<210> 24

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (1)

<223> Asp in position 1 is modified by a
1-aminocyclo-hexane carboxylic acid group

<220>

<221> MOD_RES

<222> (18)

<223> Arg in position 18 is modified by a
beta-acetyl-2,3-diamino propionic acid group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 24

Asp Lys Gly Ala Phe Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile Tyr
1 5 10 15

Asn Arg

<210> 25

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (19)

<223> Arg in position 19 is modified by a
beta-acetyl-2,3-diamino propionic acid group

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 25

Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15

Tyr Asn Arg

<210> 26

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<221> PEPTIDE

<222> (1)..(20)

<223> all amino acid residues are in the D configuration

<220>

<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 26

Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro Arg Pro Ile
1 5 10 15Tyr Asn Arg Asn
20

<210> 27

<211> 26

<212> PRT

<213> Melittin

<220>

<221> MOD_RES

<222> (26)

<223> AMIDATION

<400> 27

Gly Ile Gly Ala Val Leu Lys Val Leu Thr Thr Gly Leu Pro Ala Leu
1 5 10 15

Ile Ser Trp Ile Lys Arg Lys Arg Gln Gln
20 25

<210> 28
<211> 15
<212> PRT
<213> T helper cell epitope

<220>
<221> MOD_RES
<222> (15)
<223> AMIDATION

<400> 28
Ala Val Tyr Thr Arg Ile Met Met Asn Gly Gly Arg Leu Lys Arg
1 5 10 15

<210> 29
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> MOD_RES
<222> (1)
<223> ACETYLATION

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 29
Lys Val Asp Lys Val
1 5

<210> 30
<211> 23
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: modification
of Pyrrhocoricin

<400> 30

Val Asp Lys Val Asp Lys Gly Ser Tyr Leu Pro Arg Pro Thr Pro Pro
 1 5 10 15

Arg Pro Ile Tyr Asn Arg Asn
 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/16989

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12, 15/63, 15/82; C07K 7/10, 9/00; A61K 37/02

US CL : 530/395; 514/2, 14, 25

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/395; 514/2, 14, 25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HOFFMAN et al. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochimica et Biophysica Acta. February 1999, Vol 1426, No. 3, pages 459-467, entire document.	1-72
Y	WO 94/05787 A1(CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 17 March 1994 (17.03.1994), entire document.	1-12, 13-20, 25, 30, 34, 36, 38, 41-47, 51
Y	EP 0 352 014 A2 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 24 January 1990 (24.01.90) , entire document.	1-72
y	US 5,874,411 A (SRIVASTAVA et al) 23 February 1999 (23.02.1999), column 2, line 34 - col. 7, line 62; and col. 13, line 52 - col. 14, line 63.	

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

23 August 2000 (23.08.2000)

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Date of mailing of the international search report

06 SEP 2000

Authorized officer

Christopher Low

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/16989

Continuation of B. **FIELDS SEARCHED** Item 3: MPSRCH- amino acid sequences; WEST- pyrrolicorin, drosocin, glycoprotein or glycopeptides, antibiotic, antimicrobial, antibacterial,

REVISED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78956 A1

(51) International Patent Classification⁷: C12N 15/12,
15/63, 15/82, C07K 7/00, 9/00

(21) International Application Number: PCT/US00/16989

(22) International Filing Date: 21 June 2000 (21.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/140,606 23 June 1999 (23.06.1999) US
60/154,135 15 September 1999 (15.09.1999) US

(71) Applicant (for all designated States except US): THE
WISTAR INSTITUTE OF ANATOMY AND BIOL-
OGY [US/US]; 3601 Spruce Street, Philadelphia, PA
19104-4268 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): OTVOS, Laszlo, Jr.
[US/US]; 801 Mockingbird Lane, Audubon, PA 19403
(US).

(74) Agents: BAK, Mary, E. et al.; Howson and Howson,
Spring House Corporate Center, P.O. Box 457, Spring
House, PA 19477 (US).

(81) Designated States (national): AU, CA, JP, US.

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

Published:
— With international search report.

(88) Date of publication of the revised international search
report: 25 May 2001

(15) Information about Correction:
see PCT Gazette No. 21/2001 of 25 May 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL PYRRHOCORICIN-DERIVED PEPTIDES, AND METHODS OF USE THEREOF

(57) Abstract: Modifications of the peptide pyrrhocoricin permit the production of a variety of anti-bacterial or anti-fungal pep-
tides having general formula R¹-Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Arg-Pro-Ile-Tyr-X'-Y'-R²[SEQ ID NO:1] or mul-
timeric compositions containing more than a single peptide of that formula. These peptides may be straight chain or cyclic peptides,
and may contain one or more non-cleavable bonds. These peptides are characterized by anti-bacterial or anti-fungal activity and
metabolic stability in mammalian serum. These peptides are useful in anti-bacterial or anti-fungal pharmaceutical compositions and
for further drug development or identification of other antibiotic or anti-fungal compounds.

0590303650

WO 00/78956 A1

(19) World Intellectual Property Organization
International Bureau



00270

(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/78956 A1

(51) International Patent Classification⁷: C12N 15/12,
15/63, 15/82, C07K 7/10, 9/00, A61K 37/02

(72) Inventor; and

(75) Inventor/Applicant (for US only): OTVOS, Laszlo, Jr.
[US/US]; 801 Mockingbird Lane, Audubon, PA 19403
(US).

(21) International Application Number: PCT/US00/16989

(22) International Filing Date: 21 June 2000 (21.06.2000)

(74) Agents: BAK, Mary, E. et al.; Howson and Howson,
Spring House Corporate Center, P.O. Box 457, Spring
House, PA 19477 (US).

(25) Filing Language: English

(81) Designated States (national): AU, CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(30) Priority Data:
60/140,606 23 June 1999 (23.06.1999) US
60/154,135 15 September 1999 (15.09.1999) US

Published:

— With international search report.

(71) Applicant (for all designated States except US): THE
WISTAR INSTITUTE OF ANATOMY AND BIOL-
OGY [US/US]; 3601 Spruce Street, Philadelphia, PA
19104-4268 (US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 00/78956 A1

(54) Title: NOVEL PYRRHOCORICIN-DERIVED PEPTIDES, AND METHODS OF USE THEREOF

(57) Abstract: Modifications of the peptide pyrrhocoricin permit the production of a variety of anti-bacterial or anti-fungal pep-
tides having general formula R¹-Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'-R²[SEQ ID NO:1] or mul-
timeric compositions containing more than a single peptide of that formula. These peptides may be straight chain or cyclic peptides,
and may contain one or more non-cleavable bonds. These peptides are characterized by anti-bacterial or anti-fungal activity and
metabolic stability in mammalian serum. These peptides are useful in anti-bacterial or anti-fungal pharmaceutical compositions and
for further drug development or identification of other antibiotic or anti-fungal compounds.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/16989

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12, 15/63, 15/82; C07K 7/10, 9/00; A61K 37/02
US CL : 530/395; 514/2, 14, 25

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/395; 514/2, 14, 25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HOFFMAN et al. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochimica et Biophysica Acta. February 1999, Vol 1426, No. 3, pages 459-467, entire document.	1-72
Y	WO 94/05787 A1(CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 17 March 1994 (17.03.1994), entire document.	1-12, 13-20, 25, 30, 34, 36, 38, 41-47, 51
Y	EP 0 352 014 A2 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 24 January 1990 (24.01.90) , entire document.	1-72
y	US 5,874,411 A (SRIVASTAVA et al) 23 February 1999 (23.02.1999), column 2, line 34 - col. 7, line 62; and col. 13, line 52 - col. 14, line 63.	

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 August 2000 (23.08.2000)

Date of mailing of the international search report

06 SEP 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Christopher Low

Telephone No. 703-308-0196

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum)

WST91BPCT

Box No. I TITLE OF INVENTION

NOVEL PYRRHOCORICIN-DERIVED PEPTIDES, AND METHODS OF USE THEREOF

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

The Wistar Institute of Anatomy and Biology
3601 Spruce Street
Philadelphia, Pennsylvania 19104-4268
United States

☐ This person is also inventor.

Telephone No.

215-898-3700

Facsimile No.

215-898-3868

Teleprinter No.

State (that is, country) of nationality:

United States

State (that is, country) of residence:

United States

This person is applicant for the purposes of:

☐ all designated States

☒ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

Otvos Jr., Laszlo
801 Mockingbird Lane
Audubon, Pennsylvania 19403
United States

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

United States

State (that is, country) of residence:

United States

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

☒ agent

☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Bak, Mary E.
Howson and Howson
Spring House Corporate Center
P.O. Box 457
Spring House, Pennsylvania 19477
United States

Telephone No.

215-540-9200

Facsimile No.

215-540-5818

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☐ **AP** ARIPO Patent: GI Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☐ **EA** Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP** European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☐ **OA** OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|--|--|
| <input type="checkbox"/> AE United Arab Emirates | <input type="checkbox"/> LR Liberia |
| <input type="checkbox"/> AL Albania | <input type="checkbox"/> LS Lesotho |
| <input type="checkbox"/> AM Armenia | <input type="checkbox"/> LT Lithuania |
| <input type="checkbox"/> AT Austria | <input type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input type="checkbox"/> LV Latvia |
| <input type="checkbox"/> AZ Azerbaijan | <input type="checkbox"/> MA Morocco |
| <input type="checkbox"/> BA Bosnia and Herzegovina | <input type="checkbox"/> MD Republic of Moldova |
| <input type="checkbox"/> BB Barbados | <input type="checkbox"/> MG Madagascar |
| <input type="checkbox"/> BG Bulgaria | <input type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input type="checkbox"/> BR Brazil | |
| <input type="checkbox"/> BY Belarus | <input type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> CA Canada | <input type="checkbox"/> MW Malawi |
| <input type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input type="checkbox"/> MX Mexico |
| <input type="checkbox"/> CN China | <input type="checkbox"/> NO Norway |
| <input type="checkbox"/> CR Costa Rica | <input type="checkbox"/> NZ New Zealand |
| <input type="checkbox"/> CU Cuba | <input type="checkbox"/> PL Poland |
| <input type="checkbox"/> CZ Czech Republic | <input type="checkbox"/> PT Portugal |
| <input type="checkbox"/> DE Germany | <input type="checkbox"/> RO Romania |
| <input type="checkbox"/> DK Denmark | <input type="checkbox"/> RU Russian Federation |
| <input type="checkbox"/> DM Dominica | <input type="checkbox"/> SD Sudan |
| <input type="checkbox"/> EE Estonia | <input type="checkbox"/> SE Sweden |
| <input type="checkbox"/> ES Spain | <input type="checkbox"/> SG Singapore |
| <input type="checkbox"/> FI Finland | <input type="checkbox"/> SI Slovenia |
| <input type="checkbox"/> GB United Kingdom | <input type="checkbox"/> SK Slovakia |
| <input type="checkbox"/> GD Grenada | <input type="checkbox"/> SL Sierra Leone |
| <input type="checkbox"/> GE Georgia | <input type="checkbox"/> TJ Tajikistan |
| <input type="checkbox"/> GI Ghana | <input type="checkbox"/> TM Turkmenistan |
| <input type="checkbox"/> GM Gambia | <input type="checkbox"/> TR Turkey |
| <input type="checkbox"/> HR Croatia | <input type="checkbox"/> TT Trinidad and Tobago |
| <input type="checkbox"/> HU Hungary | <input type="checkbox"/> TZ United Republic of Tanzania |
| <input type="checkbox"/> ID Indonesia | <input type="checkbox"/> UA Ukraine |
| <input type="checkbox"/> IL Israel | <input type="checkbox"/> UG Uganda |
| <input type="checkbox"/> IN India | <input checked="" type="checkbox"/> US United States of America |
| <input type="checkbox"/> IS Iceland | |
| <input checked="" type="checkbox"/> JP Japan | <input type="checkbox"/> UZ Uzbekistan |
| <input type="checkbox"/> KE Kenya | <input type="checkbox"/> VN Viet Nam |
| <input type="checkbox"/> KG Kyrgyzstan | <input type="checkbox"/> YU Yugoslavia |
| <input type="checkbox"/> KP Democratic People's Republic of Korea | <input type="checkbox"/> ZA South Africa |
| | <input type="checkbox"/> ZW Zimbabwe |
| <input type="checkbox"/> KR Republic of Korea | |
| <input type="checkbox"/> KZ Kazakhstan | |
| <input type="checkbox"/> LC Saint Lucia | |
| <input type="checkbox"/> LK Sri Lanka | |

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Supplemental Box If the Supplemental Box is not used, this sheet should not be included in the request.

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
 - (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI) patent for the purposes of which the named person is applicant;
 - (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI) patent for the purposes of which the named person is inventor;
 - (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
 - (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
 - (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
 - (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed.
2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.
3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

"Continuation of Box No. IV"

Kita, Stanley B.
Smith, George A., Jr.
Kodroff, Cathy A.
Bak, William

All above attorneys are members of the firm of Howson and Howson.
Address of all is indicated in Box IV.

Box No. VI PRIORITY CLAIM ☐ Further priority claims are indicated in the Supplemental Box.

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 23 June 1999	60/140,606	United States		
item (2) 15 September 1999	60/154,135	United States		
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1) & (2)

* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY

Choice of International Searching Authority (ISA)
(if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA / US

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year)

Number

Country (or regional Office)

Box No. VIII CHECK LIST; LANGUAGE OF FILING

This international application contains the following number of sheets:

request : 4

description (excluding sequence listing part) : 41

claims : 12

abstract : 1

drawings : 3

sequence listing part of description : 16

Total number of sheets : 77

This international application is accompanied by the item(s) marked below:

- ☐ fee calculation sheet
- ☐ separate signed power of attorney
- ☒ copy of general power of attorney; reference number, if any:
- ☐ statement explaining lack of signature
- ☐ priority document(s) identified in Box No. VI as item(s):
- ☐ translation of international application into (language):
- ☐ separate indications concerning deposited microorganism or other biological material
- ☒ nucleotide and/or amino acid sequence listing in computer readable form
- ☒ other (specify): transmittal letter to the USRO

Figure of the drawings which should accompany the abstract:

Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

By:

Mary E. Bak
Mary E. Bak
Attorney for Applicants

For receiving Office use only

1. Date of actual receipt of the purported international application:	2. Drawings:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	<input type="checkbox"/> received:
4. Date of timely receipt of the required corrections under PCT Article 11(2):	<input type="checkbox"/> not received:
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

PATENT COOPERATION TREATY


From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

To: MARY E. BAK
HOWSON AND HOWSON
SPRING HOUSE CORPORATE CENTER
P.O. BOX 457
SPRING HOUSE PA 19477



Date of Mailing
(day/month/year)

10 OCT 2001

Applicant's or agent's file reference

WST91BPCT

IMPORTANT NOTIFICATION

International application No.

PCT/US00/16989

International filing date (day/month/year)

21 JUNE 2000

Priority Date (day/month/year)

23 JUNE 1999

Applicant

THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB 301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HOPE ROBINSON

Telephone No. (703) 308-0196

PATENT COOPERATION TREATY


PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WST91BPCT	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/116)	
International application No. PCT/US00/16989	International filing date (day/month/year) 21 JUNE 2000	Priority date (day/month/year) 23 JUNE 1999
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 15/12; C07K 9/00; A61K 37/02 and US Cl.: 530/350, 300; 435/7.1		
Applicant THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2.	This REPORT consists of a total of <u>5</u> sheets. <input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of <u>3</u> sheets.
3.	This report contains indications relating to the following items: <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 16 JANUARY 2001	Date of completion of this report 31 AUGUST 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer  HOPE ROBINSON
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/16989

I. Basis of the report**1. With regard to the elements of the international application:***

- ☐ the international application as originally filed
- ☒ the description:
pages _____ (See Attached) _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☒ the claims:
pages _____ (See Attached) _____, as originally filed
pages _____, as amended (together with any statement) under Article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☒ the drawings:
pages _____ (See Attached) _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☒ the sequence listing part of the description:
pages _____ (See Attached) _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages _____ NONE _____
- ☒ the claims, Nos. _____ NONE _____
- ☒ the drawings, sheets/figs _____ NONE _____

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/16989

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 20, 38, 45, 46, 69, 72

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 20, 38, 45, 46, 69, 72 are so

Claims 20, 38, 45, 46, 69 and 72 will not be examined because no meaningful report could be formed as the claims are improper multiple dependents.

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. _.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/16989

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Inventive Step (IS)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Industrial Applicability (IA)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-19, 21-37, 39-44, 47-68, 70-71 and 73-75 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a sequence where the Thr residue is not glycosylated and R¹ is not L-Val as the amended claims now recite. Therefore, the claimed invention meet the novelty criteria.

Applicant's amendment filed 13 July 13 has been received and entered. The amendments to the claims was sufficient to over the issues raised.

----- NEW CITATIONS -----
NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/16989

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-41, as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the claims,
page(s) 44-47, 50-52, as originally filed.
page(s) 42, 43, 48, 49 and 53, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the drawings,
page(s) 1-3, as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) 1-16, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

V. 1. REASONED STATEMENTS:

The report as to Novelty was positive (YES) with respect to claims 1-19, 21-37, 39-44, 47-68, 70-71 and 73-75.

The report as to Novelty was negative (NO) with respect to claims NONE.

The report as to Inventive Step was positive (YES) with respect to claims 1-19, 21-37, 39-44, 47-68, 70-71 and 73-75.

The report as to Inventive Step was negative (NO) with respect to claims NONE.

The report as to Industrial Applicability was positive (YES) with respect to claims 1-19, 21-37, 39-44, 47-68, 70-71 and 73-75.

The report as to Industrial Applicability was negative (NO) with respect to claims NONE.

WHAT IS CLAIMED IS:

1. A peptide of the formula R^1 -Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'- R^2 SEQ ID NO: 1,

wherein R^1 is a moiety having a net positive charge;

wherein R^2 is selected from the group consisting of a free hydroxyl, an amide, an imide, a sugar, and a sequence of one or up to about 15 additional amino acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar, said additional amino acids being independently selected from L-configuration or D-configuration and said additional amino acids capable of cyclizing the peptide by bridging between the N- and C- termini thereof;

wherein X and Y form a dipeptide selected from the group consisting of Ser-Tyr and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage; and

wherein X' and Y' form a dipeptide selected from the group consisting of Asn-Arg, and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage

2. The peptide according to claim 1, wherein R^1 is selected from the group consisting of (a) a straight chain, branched, cyclic or heterocyclic alkyl group, (b) a straight chain, branched, cyclic or heterocyclic alkanoyl group, (c) a positively charged reporter group; and (d) between 1 to 15 additional amino acids independently selected from L-configuration or D-configuration; said additional amino acids optionally substituted by one or more of (a), (b) or (c), and said additional amino acids capable of cyclizing the peptide by bridging between the N- and C- termini thereof.

3. The peptide according to claim 2, wherein said R¹ group (d) are amino acids which have been cyclized by the insertion into the structure of the amino acid of modifying sugars or imide.

4. The peptide according to claim 2, wherein said R¹ group (a) is 1-aminocyclo-hexane carboxylic acid.

5. The peptide according to claim 2, wherein said R¹ group (d) is selected from the additional amino acid residues L-Val-, D-Val-, Arg-Val-, Lys-Val-, Lys-Val-Asp-Lys-Val- SEQ ID NO: 5, and -Arg-Pro-Pro-Thr-Pro-Arg-Pro-Leu-Lys-Val- SEQ ID NO: 3.

6. The peptide according to claim 1, wherein said R¹ group is selected from Acetyl-Arg-Val-; Acetyl-Lys-Val-; and Acetyl-Lys-Val-Asp-Lys-Val- SEQ ID NO: 29.

7. The peptide according to claim 2, wherein said R¹ group (c) is biotin.

8. The peptide according to claim 2 wherein said R¹ group provides a detectable signal, optionally upon interaction with other compounds.

9. The peptide according to claim 8 wherein said R¹ group (c) is 5(6) carboxyfluorescein.

10. The peptide according to claim 2 wherein R¹ group (c) is radioactive.

11. The peptide according to claim 2 wherein R¹ group (d) is a spacer interposed between the N- terminus and C- terminus of said peptide, permitting cyclization of said peptide.

39. The peptide according to claim 1 wherein at least one conventional amide bond between two amino acids in said sequence is replaced with a non-cleavable bond.

40. The peptide according to claim 39, wherein said non-cleavable bond is a thio-amide bond or a reduced amide bond.

41. A composition comprising multiple peptides of the formula
R¹-Asp-Lys-Gly-X-Y-Leu-Pro-Arg-Pro-Thr-Pro-Pro-Arg-Pro-Ile-Tyr-X'-Y'-R² SEQ
ID NO:1,

wherein R¹ is a moiety having a net positive charge;

wherein R² is selected from the group consisting of a free hydroxyl, an amide, an imide, a sugar, and a sequence of one or up to about 5 additional amino acids, optionally substituted with a free hydroxyl, an amide, an imide or a sugar, said additional amino acids being independently selected from L-configuration or D-configuration and said additional amino acids capable of cyclizing the peptide by bridging between the - and C- termini thereof;

wherein X and Y form a dipeptide selected from the group consisting of Ser-Tyr and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage,

wherein X' and Y' form a dipeptide selected from the group consisting of Asn-Arg, and a dipeptide formed of naturally occurring amino acids or unnatural amino acids, said dipeptide resistant to cleavage.

42. The composition according to claim 41, comprising at least two peptides, wherein the second peptide is attached to any amino acid of the first peptide.

43. The composition according to claim 42, wherein additional peptides are attached to any amino acid of the other peptides in the composition.

44. The composition according to claim 41, comprising at least two said peptides, wherein at least one or more of said peptides is attached to a carrier.

45. The composition according to claim 41, comprising at least two peptides of claim 1, wherein the second or additional peptides is attached to a branched construct of the other peptides in the composition.

46. The composition according to claim 41, comprising at least two peptides of claim 1, wherein each additional peptide is covalently linked to R² of another peptide in the composition.

47. The composition according to claim 41, which comprises a multiple antigenic peptide.

48. The composition according to claim 47, wherein said multiple antigenic peptide comprises a β -alanine substituent on a poly-lysine core.

49. The composition according to claim 47, comprising at least four peptides.

72. A compound produced or identified by the method of claim 68 or 69.

REVISED
VERSION

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/16989

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12, 15/63, 15/82; C07K 7/00, 9/00
US CL : 530/395; 514/2, 14, 25

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/395; 514/2, 14, 25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	HOFFMAN et al. Range of activity and metabolic stability of synthetic antibacterial glycopeptides from insects. Biochimica et Biophysica Acta. February 1999, Vol 1426, No. 3, pages 459-467, entire document.	1-72
Y	WO 94/05787 A1(CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE) 17 March 1994 (17.03.1994), entire document.	1-12, 13-20, 25, 30, 34, 36, 38, 41-47, 51
Y	EP 0 352 014 A2 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 24 January 1990 (24.01.1990), entire document.	1-72
y	US 5,874,411 A (SRIVASTAVA et al) 23 February 1999 (23.02.1999), column 2, line 34 - col. 7, line 62; and col. 13, line 52 - col. 14, line 63.	1-72

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" documents which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" documents referring to an oral disclosure, use, exhibition or other means

"P" documents published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z"

document member of the same patent family

Date of the actual completion of the international search

23 August 2000 (23.08.2000)

Date of mailing of the international search report

6 September 2000

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box 1CT

Washington, D.C. 20531

Facsimile No. (703)305-3230

Authorized officer

Christopher Low

Telephone No. 703-308-0196

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ US

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only			
Identification of IPEA		Date of receipt of DEMAND	
Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or agent's file reference WST91BPCT	
International application No. PCT/US00/16989	International filing date (day/month/year) 21 June 2000 (21.06.00)	(Earliest) Priority date (day/month/year) 23 June 1999 (23.06.99)	
Title of invention NOVEL PYRRHOCORICIN-DERIVED PEPTIDES, AND METHODS OF USE THEREOF			
Box No. II APPLICANT(S)			
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) The Wistar Institute of Anatomy and Biology 3601 Spruce Street Philadelphia, Pennsylvania 19104-4268 United States		Telephone No.: 215-898-3700	
		Facsimile No.: 215-898-3868	
		Teleprinter No.:	
State (that is, country) of nationality: US		State (that is, country) of residence: US	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) Otvos, Laszlo, Jr. 801 Mockingbird Lane Audubon, Pennsylvania 19403 United States			
State (that is, country) of nationality: US		State (that is, country) of residence: US	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) 			
State (that is, country) of nationality:		State (that is, country) of residence:	
<input type="checkbox"/> Further applicants are indicated on a continuation sheet.			

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCEThe following person is ☒ agent ☐ common representativeand ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*Bak, Mary E.
Howson and Howson
Spring House Corporate Center
P.O. Box 457
Spring House, Pennsylvania 19477
United States

Telephone No.:

215-540-9200

Facsimile No.:

215-540-5818

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.**Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION****Statement concerning amendments:***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filedthe description ☐ as originally filed☐ as amended under Article 34the claims ☐ as originally filed☐ as amended under Article 19 (together with any accompanying statement)☐ as amended under Article 34the drawings ☐ as originally filed☐ as amended under Article 342. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). *(This check-box may be marked only where the time limit under Article 19 has not yet expired.)*

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: English☒ which is the language in which the international application was filed.☐ which is the language of a translation furnished for the purposes of international search.☐ which is the language of publication of the international application.☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.**Box No. V ELECTION OF STATES**The applicant hereby elects all eligible States *(that is, all States which have been designated and which are bound by Chapter II of the PCT)*

excluding the following States which the applicant wishes not to elect:

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- | | | |
|--|---|--------|
| 1. translation of international application | : | sheets |
| 2. amendments under Article 34 | : | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : | sheets |
| 4. copy (or, where required, translation) of statement under Article 19 | : | sheets |
| 5. letter | : | sheets |
| 6. other (<i>specify</i>) | : | sheets |

For International Preliminary
Examining Authority use only

- | received | not received |
|--------------------------|--------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |

The demand is also accompanied by the item(s) marked below:

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> fee calculation sheet | 4. <input type="checkbox"/> statement explaining lack of signature |
| 2. <input type="checkbox"/> separate signed power of attorney | 5. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable form |
| 3. <input type="checkbox"/> copy of general power of attorney, reference number, if any: | 6. <input type="checkbox"/> other (<i>specify</i>): |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

By:

Mary E. Bak

Mary E. Bak
Attorney for Applicants

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.

☐ The applicant has been informed accordingly.

4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.

5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

TENT COOPERATION TREATY


From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To: MARY E. BAK
HOWSON AND HOWSON
SPRING HOUSE CORPORATE CENTER
P.O. BOX 457
SPRING HOUSE PA 19477

PCT

WRITTEN OPINION

(PCT Rule 66)



Date of Mailing
(day/month/year)

29 MAY 2001

Applicant's or agent's file reference

WST91BPCT

REPLY DUE

within TWO months
from the above date of mailing

International application No.

PCT/US00/16989

International filing date (day/month/year)

21 JUNE 2000

Priority date (day/month/year)

23 JUNE 1999

International Patent Classification (IPC) or both national classification and IPC
IPC(7): C12N 15/12; C07K 9/00; A61K 37/02 and US Cl.: 530/350, 300; 435/7.1

Applicant

THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY

ENTERED

DUE 7-29-01

1. This written opinion is the first (first, etc.) drawn by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

When? See the time limit indicated above. ~~The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).~~

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 23 OCTOBER 2001

Name and mailing address of the IPEA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HOPE ROBINSON

Telephone No. (703) 308-6196

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

I. Basis of the opinion**1. With regard to the elements of the international application:***☒ the international application as originally filed☒ the description:

pages 1-41, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the claims:

pages 42-53, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the drawings:

pages 1-3, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

☒ the sequence listing part of the description:

pages 1-16, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written opinion was drawn on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
☒ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☐ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
☒ the claims, Nos. NONE
☒ the drawings, sheets/fig NONE

5. ☐ This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims	<u>5-29, 31-72</u>	YES
	Claims	<u>1-4, 30</u>	NO
Inventive Step (IS)	Claims	<u>5-29, 31-72</u>	YES
	Claims	<u>1-4, 30</u>	NO
Industrial Applicability (IA)	Claims	<u>1-72</u>	YES
	Claims	<u>NONE</u>	NO

2. citations and explanations

Claims 1-4 and 30 lack novelty under PCT Article 33(2) as being anticipated by Hoffman et al. (Biochimica et Biophysica Acta, Vol. 1426, 1999, pages 459-467).

Hoffman disclose a peptide which consists of the formula contained in SEQ ID Nos: 1 and 16 with a 100% sequence identity (see claims 1 and 30). Furthermore, Hoffman disclose antibacterial glycopeptides isolated from insects that have incorporated O-linked sugars. Moreover, the reference discloses compounds such as pyrrocoricin and dorsocin and the N-terminal proline-rich region of dipterocin (has an additional O-glycosylation site) which shows a great deal of amino acid and carbohydrate homology. Therefore, the reference anticipates the claimed invention.

Claims 1-4 and 30 lack an inventive step under PCT Article 33(3) as being obvious over Hoffman et al. ((Biochimica et Biophysica Acta, Vol. 1426, 1999, pages 459-467). As the reference anticipates the claimed invention, the invention also lacks an inventive step.

Claims 5-29 and 31-72 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest peptides comprising the claimed sequences. Thus, the claimed invention meets the PCT Article requirement.

----- NEW CITATIONS -----
NONE

WRITTEN OPINION

International application No.

PCT/US00/16989

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

TIME LIMIT:

The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.